400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Epigenetics / HDAC / 伏立诺他
CAS No.: 149647-78-9
Synonyms: SAHA;Suberoylanilide hydroxamic acid;MK0683
Vorinostat is an HDAC1/3 inhibitor with IC50 of ~10 nM.
生物活性
靶点 | HDAC1 IC50:~10nM | HDAC3 IC50:~10nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00771472 | Lymphoma | Phase 1 | Completed | - | - |
NCT00771472 | - | - | Completed | - | - |
NCT01064921 | Stage III Squamous Cell Carcin... more >>oma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Collapse << | Phase 1 | Completed | - | United States, Ohio ... more >> The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Collapse << |
实验方案
技术信息
CAS号 | 149647-78-9 | 储存条件 |
|
|||||||||||||
分子式 | C14H20N2O3 | 运输 | 蓝冰 | |||||||||||||
分子量 | 264.32 | 别名 | SAHA;Suberoylanilide hydroxamic acid;MK0683;M344;CCRIS 8456;HSDB 7930;Zolinza;伏立诺他 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
22RV1 | - | Growth Inhibition Assay | - | IC50=2.59274 μM | SANGER |
5637 | - | Growth Inhibition Assay | - | IC50=2.32129 μM | SANGER |
639-V | - | Growth Inhibition Assay | - | IC50=3.46057 μM | SANGER |
647-V | - | Growth Inhibition Assay | - | IC50=5.99148 μM | SANGER |
697 | - | Growth Inhibition Assay | - | IC50=473.41 nM | SANGER |
769-P | - | Growth Inhibition Assay | - | IC50=5.86718 μM | SANGER |
786-0 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=3.2 μM | 22435669 |
786-0 | - | Growth Inhibition Assay | - | IC50=4.78773 μM | SANGER |
8305C | - | Growth Inhibition Assay | - | IC50=2.86645 μM | SANGER |
8505C | - | Growth Inhibition Assay | - | IC50=1.02331 μM | SANGER |
8-MG-BA | - | Growth Inhibition Assay | - | IC50=2.33906 μM | SANGER |
A101D | - | Growth Inhibition Assay | - | IC50=2.20303 μM | SANGER |
A172 | - | Growth Inhibition Assay | - | IC50=7.86172 μM | SANGER |
A20 | - | Kinase Assay | 1 h | anti-HDAC1 activity with IC50 of 0.112 μM | 11960489 |
A204 | - | Growth Inhibition Assay | - | IC50=4.35803 μM | SANGER |
A2058 | - | Growth Inhibition Assay | - | IC50=5.05908 μM | SANGER |
A2780 | - | Growth Inhibition Assay | 96 h | IC50=1.62 μM | 21634430 |
A2780 | - | Growth Inhibition Assay | - | IC50=4.05966 μM | SANGER |
A2780 CisR | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.44 μM | 23252603 |
A375 | - | Growth Inhibition Assay | - | IC50=10.2452 μM | SANGER |
A388 | - | Growth Inhibition Assay | - | IC50=19.0303 μM | SANGER |
A3-KAW | - | Growth Inhibition Assay | - | IC50=400.59 nM | SANGER |
A427 | - | Growth Inhibition Assay | - | IC50=920.84 nM | SANGER |
A431 | - | Cytotoxic Assay | 72 h | IC50=4.2 μM | 17691763 |
A431 | - | Cytotoxic Assay | 72 h | Cytotoxicity against human A431 cells overexpressing EGFR with IC50 of 4.2 μM | 21080629 |
A431 | - | Growth Inhibition Assay | - | IC50=2.56335 μM | SANGER |
A498 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.6 μM | 22435669 |
A498 | - | Growth Inhibition Assay | - | IC50=3.20871 μM | SANGER |
A4-Fuk | - | Growth Inhibition Assay | - | IC50=644.91 nM | SANGER |
A549 | 5 μM | Function Assay | 3 h | Induction of autophagy in human A549 cells assessed as increase in LC3II | 20855208 |
A549 | - | Cytotoxic Assay | 72 h | Cytotoxicity against human A549 cells overexpressing HDAC with IC50 of 1.8 μM | 21080629 |
A549 | - | Growth Inhibition Assay | - | IC50=1.079 μM | 23644210 |
A549 | 5 μM | Function Assay | 3 h | does not induce autophagy assessed as increase in LC3II | 20855208 |
A549 | - | Growth Inhibition Assay | - | IC50=2.44893 μM | SANGER |
A549/ATCC | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.6 μM | 22435669 |
A673 | - | Growth Inhibition Assay | - | IC50=2.25862 μM | SANGER |
A704 | - | Growth Inhibition Assay | - | IC50=5.0306 μM | SANGER |
ABC-1 | - | Growth Inhibition Assay | - | IC50=2.6046 μM | SANGER |
ACHN | - | Growth Inhibition Assay | 21 h | GI50=0.65 μM | 17662606 |
ACHN | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
ACHN | - | Growth Inhibition Assay | - | IC50=9.24975 μM | SANGER |
ACN | - | Growth Inhibition Assay | - | IC50=10.8679 μM | SANGER |
ALL-PO | - | Growth Inhibition Assay | - | IC50=814.66 nM | SANGER |
AM-38 | - | Growth Inhibition Assay | - | IC50=2.77355 μM | SANGER |
AN3-CA | - | Growth Inhibition Assay | - | IC50=6.03441 μM | SANGER |
ARP1 | 2 μM | Function Assay | 6 h | Induction of P21WAF1 gene expression | 14734806 |
AsPC1 | 30 μM | Growth Inhibition Assay | 48 h | IC50=3.66 μM | 24185378 |
AsPC-1 | - | Growth Inhibition Assay | - | IC50=2.7117 μM | SANGER |
ATN-1 | - | Growth Inhibition Assay | - | IC50=740.28 nM | SANGER |
AU565 | - | Growth Inhibition Assay | - | IC50=5.09702 μM | SANGER |
BB30-HNC | - | Growth Inhibition Assay | - | IC50=10.8711 μM | SANGER |
BB49-HNC | - | Growth Inhibition Assay | - | IC50=12.3956 μM | SANGER |
BB65-RCC | - | Growth Inhibition Assay | - | IC50=3.03314 μM | SANGER |
BCPAP | - | Growth Inhibition Assay | - | IC50=501.42 nM | SANGER |
BE(2)-C | - | Growth Inhibition Assay | 72 h | IC70=2 μM | 22932316 |
BE-13 | - | Growth Inhibition Assay | - | IC50=526.96 nM | SANGER |
Becker | - | Growth Inhibition Assay | - | IC50=3.75012 μM | SANGER |
Bel7402 | - | Growth Inhibition Assay | 72 h | GI90=17 μM | 23061376 |
Bel7404 | - | Growth Inhibition Assay | 72 h | GI90=18 μM | 23061376 |
BEN | - | Growth Inhibition Assay | - | IC50=9.82159 μM | SANGER |
BFTC-905 | - | Growth Inhibition Assay | - | IC50=2.85523 μM | SANGER |
BFTC-909 | - | Growth Inhibition Assay | - | IC50=7.00641 μM | SANGER |
BGC823 | - | Growth Inhibition Assay | 72 h | GI90=7.5 μM | 23061376 |
BGC823 | - | Growth Inhibition Assay | - | GI50=3.09 μM | 23601706 |
BHK | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC7 expressed assessed as increase in plasma membrane Fdelta508 CFTR protein | 19966789 |
BHT-101 | - | Growth Inhibition Assay | - | IC50=244.18 nM | SANGER |
BHY | - | Growth Inhibition Assay | - | IC50=4.12495 μM | SANGER |
BJ | 100 μM | Growth Inhibition Assay | 48 h | Growth inhibition at 0.05 to 100 uM | 20143840 |
BPH-1 | - | Growth Inhibition Assay | - | IC50=2.6585 μM | SANGER |
BT-20 | - | Growth Inhibition Assay | - | IC50=4.79429 μM | SANGER |
BT-474 | - | Growth Inhibition Assay | - | IC50=3.6331 μM | SANGER |
BT549 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
BV-173 | - | Growth Inhibition Assay | - | IC50=1.47291 μM | SANGER |
BxPC3 | - | Growth Inhibition Assay | 72 h | IC50=2.7 μM | 20143778 |
BxPC-3 | - | Growth Inhibition Assay | - | IC50=11.3747 μM | SANGER |
C2BBe1 | - | Growth Inhibition Assay | - | IC50=472.19 nM | SANGER |
C32 | - | Growth Inhibition Assay | - | IC50=6.13034 μM | SANGER |
C-33-A | - | Growth Inhibition Assay | - | IC50=45.3256 μM | SANGER |
C3A | - | Growth Inhibition Assay | - | IC50=7.3452 μM | SANGER |
C8166 | - | Growth Inhibition Assay | - | IC50=2.21334 μM | SANGER |
Ca9-22 | - | Growth Inhibition Assay | - | IC50=1.05107 μM | SANGER |
Caco-2 | 100 μM | Growth Inhibition Assay | 48h | IC50=8.1 μM | 20143840 |
Caco-2 | 5 μM | Kinase Assay | 4 h | Induction of HDAC-mediated histone acetylation IC50 of 0.037 μM | 20143840 |
Caco-2 | 0.316 nM to 31.6 μM | Kinase Assay | 4 h | Ex vivo inhibition of human HDAC1 with IC50 of 0.119 μM | 20143840 |
Caco-2 | 0.316 nM to 31.6 μM | Kinase Assay | 4 h | Ex vivo inhibition of human HDAC3 with IC50 of 0.147 μM | 20143840 |
Caco-2 | 6.32 nM to 632 μM | Kinase Assay | 4 h | Ex vivo inhibition of human HDAC5 with IC50 of 12.6 μM | 20143840 |
Caco-2 | 6.32 nM to 632 μM | Kinase Assay | 4 h | Ex vivo inhibition of human HDAC7 with IC50 of 41 μM | 20143840 |
Caco-2 | 0.316 nM to 31.6 μM | Kinase Assay | 4 h | Ex vivo inhibition of human HDAC6 | 20143840 |
Caco-2 | 5 μM | Function Assay | 24 h | does not induce P21WAF1 gene expression | 20143840 |
CAKI-1 | - | Growth Inhibition Assay | - | IC50=3.89052 μM | SANGER |
CAL-120 | - | Growth Inhibition Assay | - | IC50=4.38992 μM | SANGER |
CAL-12T | - | Growth Inhibition Assay | - | IC50=4.13103 μM | SANGER |
Cal27 | - | Cytotoxic Assay | 72 h | IC50=3.2 μM | 17691763 |
CAL27 | - | Growth Inhibition Assay | 72 h | IC50=3.72 μM | 20143778 |
CAL27 | - | Cytotoxic Assay | 72 h | Cytotoxicity against human CAL27 cells overexpressing EGFR with IC50 of 3.2 μM | 21080629 |
CAL-27 | - | Growth Inhibition Assay | - | IC50=1.70621 μM | SANGER |
CAL27 CisR | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.61 μM | 23252603 |
CAL27 sens | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.36 μM | 23252603 |
CAL-33 | - | Growth Inhibition Assay | - | IC50=4.23064 μM | SANGER |
CAL-39 | - | Growth Inhibition Assay | - | IC50=2.23626 μM | SANGER |
CAL-51 | - | Growth Inhibition Assay | - | IC50=2.16699 μM | SANGER |
CAL-54 | - | Growth Inhibition Assay | - | IC50=4.22381 μM | SANGER |
CAL-62 | - | Growth Inhibition Assay | - | IC50=3.54514 μM | SANGER |
CAL-85-1 | - | Growth Inhibition Assay | - | IC50=13.4399 μM | SANGER |
Calu-3 | - | Growth Inhibition Assay | - | IC50=5.06452 μM | SANGER |
Calu-6 | - | Growth Inhibition Assay | - | IC50=9.37528 μM | SANGER |
CAMA-1 | - | Growth Inhibition Assay | - | IC50=1.71971 μM | SANGER |
Capan1 | - | Growth Inhibition Assay | 72 h | IC50=7.3 μM | 20143778 |
CAPAN-1 | - | Growth Inhibition Assay | - | IC50=4.42382 μM | SANGER |
CaR-1 | - | Growth Inhibition Assay | - | IC50=2.86 μM | SANGER |
CAS-1 | - | Growth Inhibition Assay | - | IC50=11.4109 μM | SANGER |
Ca-Ski | - | Growth Inhibition Assay | - | IC50=3.4543 μM | SANGER |
CCD1059SK | - | Growth Inhibition Assay | - | IC50=43.5 μM | 18247554 |
CCRF-CEM | - | Cytotoxic Assay | 72 h | IC50=0.8 μM | 17691763 |
CCRF-CEM | - | Growth Inhibition Assay | - | IC50=2.53043 μM | SANGER |
CEM | - | Kinase Assay | 1 h | Inhibition of HDAC with IC50 of 0.33 μM | 16420064 |
CFBE41o | 5 μM | Kinase Assay | - | Down regulation of HDAC7 at 0.2 to 5 uM | 21984958 |
CFBE41o | 1 μM | Function Assay | 24 h | Restoration of CFTR deltaF508 mutant trafficking to cell surface as glycoforms | 21984958 |
CFBE41o- | 5 μM | Kinase Assay | 8 h | Inhibition of HDAC assessed as hyperacetylation of histone H3 | 19966789 |
CFBE41o- | 5 μM | Kinase Assay | 4 h | Inhibition of HDAC assessed as increase in mutant Fdelta508 CFTR protein level | 19966789 |
CFBE41o- | 1 μM | Kinase Assay | 1 h | Inhibition of HDAC assessed as increase in CFTR protein level | 19966789 |
CFBE41o- | 1 μM | Kinase Assay | 5 days | Inhibition of HDAC7 assessed as increase in stabilization of Fdelta508 CFTR protein | 19966789 |
CFBE41o- | 1 μM | Kinase Assay | 24 h | Inhibition of HDAC7 assessed as increase in Fdelta508 CFTR protein trafficking | 19966789 |
CFBE41o- | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC7 assessed as increase in rate of maturation of CFTR protein to its glycoform | 19966789 |
CFBE41o- | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC7 assessed as increase in stability of Fdelta508 CFTR protein | 19966789 |
CFBE41o- | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC7 assessed as correction of mutant Fdelta508 CFTR trafficking to cell surface as glycoform | 19966789 |
CFPAC-1 | - | Growth Inhibition Assay | - | IC50=7.36222 μM | SANGER |
CGTH-W-1 | - | Growth Inhibition Assay | - | IC50=1.89946 μM | SANGER |
ChaGo-K-1 | - | Growth Inhibition Assay | - | IC50=15.8359 μM | SANGER |
CHL-1 | - | Growth Inhibition Assay | - | IC50=642.08 nM | SANGER |
CHP-212 | - | Growth Inhibition Assay | - | IC50=457.53 nM | SANGER |
COLO205 | 10 μM | Kinase Assay | 24 h | Inhibition of HDAC1 assessed as induction of histone H3 acetylation with IC50 of 2.2 μM | 20451378 |
COLO205 | - | Growth Inhibition Assay | 96 h | IC50=2.12 μM | 21634430 |
COLO-320-HSR | - | Growth Inhibition Assay | - | IC50=1.88197 μM | SANGER |
COLO-668 | - | Growth Inhibition Assay | - | IC50=5.7132 μM | SANGER |
COLO-678 | - | Growth Inhibition Assay | - | IC50=27.4919 μM | SANGER |
COLO-679 | - | Growth Inhibition Assay | - | IC50=6.00255 μM | SANGER |
COLO-680N | - | Growth Inhibition Assay | - | IC50=7.9173 μM | SANGER |
COLO-684 | - | Growth Inhibition Assay | - | IC50=1.46118 μM | SANGER |
COLO-741 | - | Growth Inhibition Assay | - | IC50=4.55994 μM | SANGER |
COLO-792 | - | Growth Inhibition Assay | - | IC50=5.26356 μM | SANGER |
COLO-800 | - | Growth Inhibition Assay | - | IC50=1.71179 μM | SANGER |
COLO-824 | - | Growth Inhibition Assay | - | IC50=7.72863 μM | SANGER |
COLO-829 | - | Growth Inhibition Assay | - | IC50=3.50073 μM | SANGER |
COR-L105 | - | Growth Inhibition Assay | - | IC50=4.13051 μM | SANGER |
COR-L23 | 10 μM | Growth Inhibition Assay | 72 h | GI50=1.1 μM | 21080647 |
COR-L23 | - | Growth Inhibition Assay | - | IC50=2.58566 μM | SANGER |
COR-L88 | - | Growth Inhibition Assay | - | IC50=1.56424 μM | SANGER |
CP50-MEL-B | - | Growth Inhibition Assay | - | IC50=9.92432 μM | SANGER |
CTB-1 | - | Growth Inhibition Assay | - | IC50=537.92 nM | SANGER |
CTV-1 | - | Growth Inhibition Assay | - | IC50=581.56 nM | SANGER |
CW-2 | - | Growth Inhibition Assay | - | IC50=4.19001 μM | SANGER |
D-247MG | - | Growth Inhibition Assay | - | IC50=11.1009 μM | SANGER |
D-263MG | - | Growth Inhibition Assay | - | IC50=3.82051 μM | SANGER |
D-283MED | - | Growth Inhibition Assay | - | IC50=714.14 nM | SANGER |
D-336MG | - | Growth Inhibition Assay | - | IC50=41.8442 μM | SANGER |
D-392MG | - | Growth Inhibition Assay | - | IC50=9.25715 μM | SANGER |
D-423MG | - | Growth Inhibition Assay | - | IC50=706.89 nM | SANGER |
D-502MG | - | Growth Inhibition Assay | - | IC50=8.76994 μM | SANGER |
D-566MG | - | Growth Inhibition Assay | - | IC50=838.62 nM | SANGER |
Daoy | - | Growth Inhibition Assay | - | IC50=1.76319 μM | SANGER |
DB | - | Growth Inhibition Assay | - | IC50=598.57 nM | SANGER |
DBTRG-05MG | - | Growth Inhibition Assay | - | IC50=8.87565 μM | SANGER |
DEL | - | Growth Inhibition Assay | - | IC50=1.35162 μM | SANGER |
Detroit562 | - | Growth Inhibition Assay | - | IC50=3.65022 μM | SANGER |
DJM-1 | - | Growth Inhibition Assay | - | IC50=3.37674 μM | SANGER |
DK-MG | - | Growth Inhibition Assay | - | IC50=5.18438 μM | SANGER |
DMS114 | - | Growth Inhibition Assay | 48 h | GI50=2.9 μM | 19419205 |
DMS-114 | - | Growth Inhibition Assay | - | IC50=3.47066 μM | SANGER |
DMS-273 | - | Growth Inhibition Assay | - | IC50=2.14837 μM | SANGER |
DMS-79 | - | Growth Inhibition Assay | - | IC50=5.13883 μM | SANGER |
DOHH-2 | - | Growth Inhibition Assay | - | IC50=706.68 nM | SANGER |
DOK | - | Growth Inhibition Assay | - | IC50=4.26593 μM | SANGER |
DoTc2-4510 | - | Growth Inhibition Assay | - | IC50=2.62185 μM | SANGER |
DSH1 | - | Growth Inhibition Assay | - | IC50=2.16398 μM | SANGER |
DU145 | 10 μM | Growth Inhibition Assay | 72 h | GI50=1.05 μM | 21080647 |
DU145 | 2.5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as upregulation of p21waf1 protein expression | 22260166 |
DU145 | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as histone H4 acetylation | 22260166 |
DU145 | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as histone H3 hyperacetylation | 22260166 |
DU-4475 | - | Growth Inhibition Assay | - | IC50=751.91 nM | SANGER |
ECC10 | - | Growth Inhibition Assay | - | IC50=945.87 nM | SANGER |
EC-GI-10 | - | Growth Inhibition Assay | - | IC50=3.26153 μM | SANGER |
EFM-19 | - | Growth Inhibition Assay | - | IC50=1.04879 μM | SANGER |
EFO-27 | - | Growth Inhibition Assay | - | IC50=1.25043 μM | SANGER |
EGI-1 | - | Growth Inhibition Assay | - | IC50=2.81743 μM | SANGER |
EKVX | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
EKVX | - | Growth Inhibition Assay | - | IC50=7.19267 μM | SANGER |
EM-2 | - | Growth Inhibition Assay | - | IC50=1.70014 μM | SANGER |
EOL1 | - | Cytotoxic Assay | 72 h | IC50=1 μM | 17691763 |
EoL-1-cell | - | Growth Inhibition Assay | - | IC50=45425 nM | SANGER |
EPLC-272H | - | Growth Inhibition Assay | - | IC50=4.3895 μM | SANGER |
ES1 | - | Growth Inhibition Assay | - | IC50=724.4 nM | SANGER |
ES2 | - | Growth Inhibition Assay | 48 h | IC50=12.7 μM | 23493449 |
ES3 | - | Growth Inhibition Assay | - | IC50=1.82681 μM | SANGER |
ES4 | - | Growth Inhibition Assay | - | IC50=1.78741 μM | SANGER |
ES5 | - | Growth Inhibition Assay | - | IC50=1.443 μM | SANGER |
ES6 | - | Growth Inhibition Assay | - | IC50=1.93631 μM | SANGER |
ES7 | - | Growth Inhibition Assay | - | IC50=1.54773 μM | SANGER |
ES8 | - | Growth Inhibition Assay | - | IC50=523.53 nM | SANGER |
ESS-1 | - | Growth Inhibition Assay | - | IC50=4.42724 μM | SANGER |
ETK-1 | - | Growth Inhibition Assay | - | IC50=3.94635 μM | SANGER |
EW-1 | - | Growth Inhibition Assay | - | IC50=947.26 nM | SANGER |
EW-11 | - | Growth Inhibition Assay | - | IC50=1.36026 μM | SANGER |
EW-13 | - | Growth Inhibition Assay | - | IC50=3.5251 μM | SANGER |
EW-16 | - | Growth Inhibition Assay | - | IC50=1.74107 μM | SANGER |
EW-18 | - | Growth Inhibition Assay | - | IC50=832.96 nM | SANGER |
EW-22 | - | Growth Inhibition Assay | - | IC50=1.92887 μM | SANGER |
EW-24 | - | Growth Inhibition Assay | - | IC50=1.46531 μM | SANGER |
EW-3 | - | Growth Inhibition Assay | - | IC50=1.17212 μM | SANGER |
FADU | - | Growth Inhibition Assay | - | IC50=2.47162 μM | SANGER |
Friend leukemic cell | 50 μM | Growth Inhibition Assay | 72 h | IC50=0.99 μM | 12109913 |
FTC-133 | - | Growth Inhibition Assay | - | IC50=4.79263 μM | SANGER |
G401 | - | Growth Inhibition Assay | 72 h | IC50=1 μM | 18370373 |
G-401 | - | Growth Inhibition Assay | - | IC50=3.79085 μM | SANGER |
G-402 | - | Growth Inhibition Assay | - | IC50=2.70451 μM | SANGER |
GAK | - | Growth Inhibition Assay | - | IC50=32.2616 μM | SANGER |
GAMG | - | Growth Inhibition Assay | - | IC50=2.44561 μM | SANGER |
GB-1 | - | Growth Inhibition Assay | - | IC50=2.32335 μM | SANGER |
GBC-SD | 5 μM | Growth Inhibition Assay | 72 h | IC50=14.8 μM | 23707260 |
GCIY | - | Growth Inhibition Assay | - | IC50=4.77424 μM | SANGER |
GCT | - | Growth Inhibition Assay | - | IC50=2.1777 μM | SANGER |
GI-1 | - | Growth Inhibition Assay | - | IC50=2.30543 μM | SANGER |
GI-ME-N | - | Growth Inhibition Assay | - | IC50=3.29511 μM | SANGER |
GM11272 | 100 nM | Function Assay | 72 h | Reactivation of MeCp2 mutant expression at 10 to 100 nM | 21840716 |
GM11272 | 0.1 μM | Function Assay | 72 h | does not reactivate MeCp2 mutant expression | 21840716 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | Inhibition of HDAC assessed as increase in histone H3 lysine 14 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | Inhibition of HDAC assessed as increase in histone H4 lysine 5 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | Inhibition of HDAC assessed as increase in histone H4 lysine 12 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | Inhibition of HDAC assessed as increase in histone H3 lysine 9 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | Inhibition of HDAC assessed as increase in histone H4 lysine 8 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | Inhibition of HDAC assessed as increase in histone H4 lysine 16 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | does not inhibit HDAC assessed as increase in histone H3 lysine 14 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | does not inhibit HDAC assessed as increase in histone H4 lysine 5 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | does not inhibit HDAC assessed as increase in histone H4 lysine 12 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | does not inhibit HDAC assessed as increase in histone H3 lysine 9 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | does not inhibit HDAC assessed as increase in histone H4 lysine 8 acetylation of FXN gene | 16921367 |
GM15850 | 2.5 μM | Kinase Assay | 96 h | does not inhibit HDAC assessed as increase in histone H4 lysine 16 acetylation of FXN gene | 16921367 |
GM15850 | 5 μM | Function Assay | 12 h | has no effect on FXN mRNA expression | 16921367 |
GMS-10 | - | Growth Inhibition Assay | - | IC50=4.42819 μM | SANGER |
GOTO | - | Growth Inhibition Assay | - | IC50=729.12 nM | SANGER |
GP5d | - | Growth Inhibition Assay | - | IC50=3.7295 μM | SANGER |
GR-ST | - | Growth Inhibition Assay | - | IC50=3.22139 μM | SANGER |
GT3TKB | - | Growth Inhibition Assay | - | IC50=3.11283 μM | SANGER |
H1299 | - | Kinase Assay | 20 min | Inhibitory activity against HDAC enzyme with IC50 of 0.194 μM | 14521422 |
H1299 | - | Growth Inhibition Assay | 72 h | IC50=7.24 μM | 14521422 |
H4 | - | Growth Inhibition Assay | - | IC50=1.50912 μM | SANGER |
H460 | - | Cytotoxic Assay | 12 h | IC50=0.82 μM | 24766560 |
H661 | - | Growth Inhibition Assay | 48 h | IC50=1 μM | 17157009 |
H9 | - | Growth Inhibition Assay | - | IC50=255.04 nM | SANGER |
HAL-01 | - | Growth Inhibition Assay | - | IC50=968.04 nM | SANGER |
HBC5 | - | Growth Inhibition Assay | 48 h | GI50=17 μM | 19419205 |
HC-1 | - | Growth Inhibition Assay | - | IC50=1.59866 μM | SANGER |
HCC1395 | - | Growth Inhibition Assay | - | IC50=8.05452 μM | SANGER |
HCC1419 | - | Growth Inhibition Assay | - | IC50=1.34027 μM | SANGER |
HCC1569 | - | Growth Inhibition Assay | - | IC50=4.88458 μM | SANGER |
HCC1806 | - | Growth Inhibition Assay | - | IC50=4.20312 μM | SANGER |
HCC1937 | - | Growth Inhibition Assay | - | IC50=47.1958 μM | SANGER |
HCC1954 | - | Growth Inhibition Assay | - | IC50=31.3666 μM | SANGER |
HCC2218 | - | Growth Inhibition Assay | - | IC50=958.48 nM | SANGER |
HCC2998 | - | Growth Inhibition Assay | - | IC50=9.13681 μM | SANGER |
HCC38 | - | Growth Inhibition Assay | - | IC50=10.322 μM | SANGER |
HCC70 | - | Growth Inhibition Assay | - | IC50=14.4233 μM | SANGER |
HCC827 | - | Growth Inhibition Assay | 72 h | IC50=1.8 μM | 20143778 |
HCE-4 | - | Growth Inhibition Assay | - | IC50=3.91663 μM | SANGER |
HCE-T | - | Growth Inhibition Assay | - | IC50=1.715 μM | SANGER |
HCT116 | - | Growth Inhibition Assay | 72h | IC50=0.31 μM | 19084294 |
HCT116 | 30 μM | Kinase Assay | 30 h | Inhibition of HDAC6 assessed as induction of alpha-tubulin acetylation | 21080647 |
HCT116 | 30 μM | Kinase Assay | 30 h | Inhibition of HDAC1 assessed as induction of histone H3K9 acetylation | 21080647 |
HCT116 | - | Growth Inhibition Assay | - | IC50=0.757 μM | 23644210 |
HCT116 | 0.3 μM | Kinase Assay | 30 h | does not inhibit HDAC1 assessed as induction of histone H3K9 acetylation | 21080647 |
HCT116 | 3 μM | Apoptosis Assay | 24 h | does not induce apoptosis assessed as increase in p53 protein level | 24766560 |
HCT-116 | - | Growth Inhibition Assay | - | IC50=1.1775 μM | SANGER |
HCT15 | - | Growth Inhibition Assay | 48 h | GI50=0.82 μM | 16723227 |
HCT15 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=2.5 μM | 22435669 |
HDLM-2 | - | Growth Inhibition Assay | - | IC50=47.2287 μM | SANGER |
HD-MY-Z | - | Growth Inhibition Assay | - | IC50=538.13 nM | SANGER |
HEC-1 | - | Growth Inhibition Assay | - | IC50=1.9536 μM | SANGER |
Hec-1-A | - | Cytotoxic Assay | 72 h | IC50=1 μM | 17691763 |
HEK293 | - | Kinase Assay | 1 h | Inhibition of HDAC1 with IC50 of 0.03 μM | 18308563 |
HEK293 | - | Kinase Assay | 1 h | Inhibition of HDAC3 with IC50 of 0.057 μM | 18308563 |
HEK293 | - | Kinase Assay | 3 h | Inhibition of recombinant HDAC6 expression with IC50 of 0.019 μM | 18558669 |
HEK293 | 10 μM | Function Assay | 24 h | Activation of mouse Wnt3a signaling expressed | 19022675 |
HEK293 | - | Growth Inhibition Assay | 72 h | GI50=13 μM | 24900500 |
HEK-TE | 5 μM | Function Assay | 6h | Increase in histone H3 acetylation | 18434144 |
HEL | - | Growth Inhibition Assay | 48 h | IC50=0.49 μM | 24694055 |
HEL | - | Growth Inhibition Assay | - | IC50=806.08 nM | SANGER |
HeLa | - | Kinase Assay | 30 min | Inhibitory concentration against histone deacetylase with IC50 of 0.28 μM | 15603949 |
HeLa | 10 μM | Kinase Assay | 30 min | Inhibition of recombinant HDAC1 with IC50 of 0.02 μM | 17691763 |
HeLa | - | Growth Inhibition Assay | 72 h | IC50=0.46 μM | 18370373 |
HeLa | - | Kinase Assay | 2 h | Inhibition of nuclear HDAC with IC50 of 0.083 μM | 18558669 |
HeLa | 2 μM | Kinase Assay | 30 min | Inhibition of HDAC2 in human HeLa cells with IC50 of 0.1 μM | 19084294 |
HeLa | - | Kinase Assay | 15 min | Inhibition of HDAC6 from nuclear extract with IC50 of 0.0855 μM | 19093884 |
HeLa | - | Kinase Assay | 15 min | Inhibition of HDAC8 from nuclear extract with IC50 of 1.86 μM | 19093884 |
HeLa | - | Growth Inhibition Assay | 72 h | IC50=0.46 μM | 19441846 |
HeLa | - | Cytotoxic Assay | 72 h | Cytotoxicity against human HeLa cells overexpressing HDAC with IC50 of 1.5 μM | 21080629 |
H-EMC-SS | - | Growth Inhibition Assay | - | IC50=13.9104 μM | SANGER |
Hep3B | - | Growth Inhibition Assay | 48 h | GI50=1.21 μM | 21712146 |
Hep3B | - | Growth Inhibition Assay | 48 h | GI50=0.69 μM | 22439863 |
HepG2 | - | Growth Inhibition Assay | - | IC50=0.0006 μM | 18247554 |
HepG2 | 5 μM | Kinase Assay | 6h | Induction of HDAC-mediated histone acetylation | 20143840 |
HepG2 | 5 μM | Kinase Assay | 6h | Induction of HDAC-mediated histone hyperacetylation | 20143840 |
HepG2 | 5 μM | Kinase Assay | 6h | Induction of HDAC-mediated alpha-tubulin acetylation | 20143840 |
HepG2 | 5 μM | Kinase Assay | 6h | Induction of HDAC-mediated H3/H4 histone acetylation | 20143840 |
HepG2 | 10 μM | Function Assay | 24 h | does not induce apoptosis assessed as hyperacetylation of p53 | 21548582 |
HGC27 | 5 μM | Growth Inhibition Assay | 72 h | IC50=5.4 μM | 23707260 |
HGC-27 | - | Growth Inhibition Assay | - | IC50=872.34 nM | SANGER |
HH | - | Growth Inhibition Assay | - | IC50=894.12 nM | SANGER |
High5 | - | Kinase Assay | 24 h | Inhibition of human recombinant HDAC6 with IC50 of 0.09 μM | 23602523 |
High5 | - | Kinase Assay | 24 h | Inhibition of human recombinant HDAC1 with IC50 of 0.12 μM | 23602523 |
High5 | - | Kinase Assay | 24 h | Inhibition of human recombinant HDAC3 with IC50 of 0.17 μM | 23602523 |
HL60 | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC | 23707260 |
HL60 | - | Growth Inhibition Assay | 72 h | GI50=0.93 μM | 24900500 |
HL-60 | - | Growth Inhibition Assay | - | IC50=1.93902 μM | SANGER |
HLE | - | Growth Inhibition Assay | - | IC50=2.08529 μM | SANGER |
HMV-II | - | Growth Inhibition Assay | - | IC50=4.5173 μM | SANGER |
HN | - | Growth Inhibition Assay | - | IC50=1.88725 μM | SANGER |
HO-1-N-1 | - | Growth Inhibition Assay | - | IC50=1.23835 μM | SANGER |
HOP92 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=4 μM | 22435669 |
HOS | - | Growth Inhibition Assay | - | IC50=2.07653 μM | SANGER |
HPAF-II | - | Growth Inhibition Assay | - | IC50=6.3548 μM | SANGER |
HPDE6c7 | 50 μM | Cytotoxic Assay | 72 h | IC50=1.3 μM | 18494463 |
Hs578T | - | Cytotoxic Assay | 48 h | GI=4.83 μM | 24015327 |
Hs-578-T | - | Growth Inhibition Assay | - | IC50=4.77655 μM | SANGER |
HS68 | 10 μM | Cytotoxic Assay | 72 h | IC50=4.6 μM | 23570542 |
HSC-2 | - | Growth Inhibition Assay | - | IC50=2.12898 μM | SANGER |
HSC3 | - | Cytotoxic Assay | 12 h | IC50=0.71 μM | 24766560 |
HSC-3 | - | Growth Inhibition Assay | - | IC50=2.44509 μM | SANGER |
HSC-4 | - | Growth Inhibition Assay | - | IC50=846.51 nM | SANGER |
HT | - | Growth Inhibition Assay | - | IC50=1.88947 μM | SANGER |
HT1080 | - | Growth Inhibition Assay | 72 h | IC50=2.4 μM | 12270175 |
HT1080 | - | Growth Inhibition Assay | - | IC50=0.0024 μM | 18247554 |
HT-1080 | - | Growth Inhibition Assay | - | IC50=2.44864 μM | SANGER |
HT-1197 | - | Growth Inhibition Assay | - | IC50=19.9227 μM | SANGER |
HT-1376 | - | Growth Inhibition Assay | - | IC50=5.78052 μM | SANGER |
HT-144 | - | Growth Inhibition Assay | - | IC50=5.24987 μM | SANGER |
HT-29 | - | Cytotoxic Assay | 12 h | IC50=0.72 μM | 24766560 |
HT-29 | - | Growth Inhibition Assay | - | IC50=3.26614 μM | SANGER |
HT-3 | - | Growth Inhibition Assay | - | IC50=2.49535 μM | SANGER |
HT55 | - | Growth Inhibition Assay | - | IC50=1.65131 μM | SANGER |
HTC-C3 | - | Growth Inhibition Assay | - | IC50=2.2685 μM | SANGER |
HuCCT1 | - | Growth Inhibition Assay | - | IC50=5.23856 μM | SANGER |
HuH-7 | - | Growth Inhibition Assay | - | IC50=2.30637 μM | SANGER |
human HOP-92 | - | Growth Inhibition Assay | - | IC50=1.94065 μM | SANGER |
Human microvascular epithelial cell | 50 μM | Cytotoxic Assay | 72 h | IC50=1.3 μM | 18494463 |
Human renal epithelial cell | - | Growth Inhibition Assay | 72 h | IC50=14 μM | 18370373 |
HuO-3N1 | - | Growth Inhibition Assay | - | IC50=1.59385 μM | SANGER |
HuO9 | - | Growth Inhibition Assay | - | IC50=1.45362 μM | SANGER |
Hup T3 | 50 μM | Cytotoxic Assay | 72h | IC50=0.8 μM | 18494463 |
HuP-T3 | - | Growth Inhibition Assay | - | IC50=5.88677 μM | SANGER |
HuP-T4 | - | Growth Inhibition Assay | - | IC50=1.493 μM | SANGER |
HUT78 | - | Growth Inhibition Assay | 72 h | GI50=0.3 μM | 20884208 |
IA-LM | - | Growth Inhibition Assay | - | IC50=1.69278 μM | SANGER |
IGR-1 | - | Growth Inhibition Assay | - | IC50=20.3117 μM | SANGER |
IGROV1 | - | Growth Inhibition Assay | 72 h | IC50=2.2 μM | 19084294 |
IGROV1 | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as p53 acetylation | 19084294 |
IGROV1 | 10 μM | Kinase Assay | 4 h | Inhibition of HDAC assessed as histone-H4 acetylation | 19084294 |
IGROV1 | 10 μM | Kinase Assay | 4 h | Inhibition of HDAC6 assessed as alpha-tubulin acetylation | 19084294 |
IGROV1 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
IST-MEL1 | - | Growth Inhibition Assay | - | IC50=6.89669 μM | SANGER |
IST-MES1 | - | Growth Inhibition Assay | - | IC50=9.51644 μM | SANGER |
IST-SL1 | - | Growth Inhibition Assay | - | IC50=2.16844 μM | SANGER |
J82 | - | Growth Inhibition Assay | - | IC50=3.5057 μM | SANGER |
JAR | - | Growth Inhibition Assay | - | IC50=2.31987 μM | SANGER |
JEG-3 | - | Growth Inhibition Assay | - | IC50=8.78618 μM | SANGER |
J-RT3-T3-5 | - | Growth Inhibition Assay | - | IC50=910.49 nM | SANGER |
Jurkat | 100 μM | Cytotoxic Assay | 72 h | GI50=0.9 μM | 24900743 |
Jurkat | 20 μM | Cytotoxic Assay | 72 h | no cytotoxicity assessed as growth inhibition | 24304348 |
Jurkat E6.1 | - | Kinase Assay | 2 h | Inhibition of HDAC4 with IC50 of 0.04 μM | 24261862 |
JVM-3 | - | Growth Inhibition Assay | - | IC50=1.85451 μM | SANGER |
K5 | - | Growth Inhibition Assay | - | IC50=2.07811 μM | SANGER |
K562 | - | Kinase Assay | 6 h | Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) with IC50 of 0.01 μM | 12419380 |
K562 | - | Growth Inhibition Assay | - | IC50=0.645 μM | 23644210 |
K562 | - | Kinase Assay | - | does not inhibit HDAC | 23591111 |
K-562 | - | Growth Inhibition Assay | - | IC50=18.6317 μM | SANGER |
KALS-1 | - | Growth Inhibition Assay | - | IC50=8.50928 μM | SANGER |
KARPAS-45 | - | Growth Inhibition Assay | - | IC50=173.89 nM | SANGER |
KASUMI-1 | - | Growth Inhibition Assay | - | IC50=99.17 nM | SANGER |
KB | - | Cytotoxic Assay | 12 h | IC50=0.75 μM | 24766560 |
KE-37 | - | Growth Inhibition Assay | - | IC50=894.62 nM | SANGER |
KG1 | - | Growth Inhibition Assay | 48 h | IC50=1.15 μM | 24525003 |
KG-1 | - | Growth Inhibition Assay | - | IC50=775.45 nM | SANGER |
KGN | - | Growth Inhibition Assay | - | IC50=12.2901 μM | SANGER |
KINGS-1 | - | Growth Inhibition Assay | - | IC50=6.26152 μM | SANGER |
KLE | - | Growth Inhibition Assay | - | IC50=9.32232 μM | SANGER |
KM12 | - | Cytotoxic Assay | 48 h | GI=1.88 μM | 24015327 |
KM12 | - | Growth Inhibition Assay | - | IC50=6.24099 μM | SANGER |
KM-H2 | - | Growth Inhibition Assay | - | IC50=3.82624 μM | SANGER |
KMOE-2 | - | Growth Inhibition Assay | - | IC50=1.09422 μM | SANGER |
KNS-42 | - | Growth Inhibition Assay | - | IC50=16.6589 μM | SANGER |
KNS-62 | - | Growth Inhibition Assay | - | IC50=2.45061 μM | SANGER |
KNS-81-FD | - | Growth Inhibition Assay | - | IC50=14.7045 μM | SANGER |
KOSC-2 | - | Growth Inhibition Assay | - | IC50=2.56076 μM | SANGER |
KP-4 | - | Growth Inhibition Assay | - | IC50=1.37085 μM | SANGER |
KP-N-YN | - | Growth Inhibition Assay | - | IC50=4.20927 μM | SANGER |
KP-N-YS | - | Growth Inhibition Assay | - | IC50=2.32615 μM | SANGER |
KS-1 | - | Growth Inhibition Assay | - | IC50=5.98836 μM | SANGER |
KU-19-19 | - | Growth Inhibition Assay | - | IC50=2.53513 μM | SANGER |
KU812 | - | Growth Inhibition Assay | - | IC50=813.1 nM | SANGER |
KURAMOCHI | - | Growth Inhibition Assay | - | IC50=28.126 μM | SANGER |
KY821 | - | Growth Inhibition Assay | - | IC50=563.25 nM | SANGER |
KYSE-140 | - | Growth Inhibition Assay | - | IC50=7.44061 μM | SANGER |
KYSE-150 | - | Growth Inhibition Assay | - | IC50=11.0387 μM | SANGER |
KYSE-180 | - | Growth Inhibition Assay | - | IC50=3.63372 μM | SANGER |
KYSE-270 | - | Growth Inhibition Assay | - | IC50=5.66031 μM | SANGER |
KYSE-410 | - | Growth Inhibition Assay | - | IC50=6.30645 μM | SANGER |
KYSE-450 | - | Growth Inhibition Assay | - | IC50=3.68582 μM | SANGER |
KYSE-510 | - | Growth Inhibition Assay | - | IC50=3.72181 μM | SANGER |
KYSE-510 CisR | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.59 μM | 23252603 |
KYSE-510 sens | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.7 μM | 23252603 |
KYSE-520 | - | Growth Inhibition Assay | - | IC50=14.927 μM | SANGER |
KYSE-70 | - | Growth Inhibition Assay | - | IC50=4.2934 μM | SANGER |
L-363 | - | Growth Inhibition Assay | - | IC50=503.1 nM | SANGER |
L-428 | - | Growth Inhibition Assay | - | IC50=3.40045 μM | SANGER |
LAMA-84 | - | Growth Inhibition Assay | - | IC50=1.43945 μM | SANGER |
LAN-6 | - | Growth Inhibition Assay | - | IC50=6.49631 μM | SANGER |
LB1047-RCC | - | Growth Inhibition Assay | - | IC50=1.18312 μM | SANGER |
LB2241-RCC | - | Growth Inhibition Assay | - | IC50=1.98231 μM | SANGER |
LB2518-MEL | - | Growth Inhibition Assay | - | IC50=3.22398 μM | SANGER |
LB771-HNC | - | Growth Inhibition Assay | - | IC50=14.419 μM | SANGER |
LB831-BLC | - | Growth Inhibition Assay | - | IC50=9.45171 μM | SANGER |
LC-2-ad | - | Growth Inhibition Assay | - | IC50=8.21937 μM | SANGER |
LCLC-103H | - | Growth Inhibition Assay | - | IC50=2.90438 μM | SANGER |
LCLC-97TM1 | - | Growth Inhibition Assay | - | IC50=2.14583 μM | SANGER |
LK-2 | - | Growth Inhibition Assay | - | IC50=10.4208 μM | SANGER |
LN-405 | - | Growth Inhibition Assay | - | IC50=5.73085 μM | SANGER |
LNCAP | - | Growth Inhibition Assay | 72 h | IC50=0.58 μM | 20143778 |
LNCaP-Clone-FGC | - | Growth Inhibition Assay | - | IC50=6.80403 μM | SANGER |
LoVo | 10 μM | Growth Inhibition Assay | 72 h | GI50=1.7 μM | 21080647 |
LoVo | - | Growth Inhibition Assay | - | IC50=1.8981 μM | SANGER |
LOXIMVI | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1 μM | 22435669 |
LOXIMVI | - | Growth Inhibition Assay | - | IC50=1.7211 μM | SANGER |
LOX-IMVI | - | Growth Inhibition Assay | 48 h | IC50=1.3 μM | 15715470 |
LS-1034 | - | Growth Inhibition Assay | - | IC50=8.57437 μM | SANGER |
LS-123 | - | Growth Inhibition Assay | - | IC50=3.87909 μM | SANGER |
LS-411N | - | Growth Inhibition Assay | - | IC50=2.8233 μM | SANGER |
LS-513 | - | Growth Inhibition Assay | - | IC50=4.42198 μM | SANGER |
LU-134-A | - | Growth Inhibition Assay | - | IC50=2.47008 μM | SANGER |
LU-135 | - | Growth Inhibition Assay | - | IC50=19.2636 μM | SANGER |
LU-139 | - | Growth Inhibition Assay | - | IC50=822.86 nM | SANGER |
LU-65 | - | Growth Inhibition Assay | - | IC50=4.07633 μM | SANGER |
LU-99A | - | Growth Inhibition Assay | - | IC50=6.55989 μM | SANGER |
LXF-289 | - | Growth Inhibition Assay | - | IC50=1.3524 μM | SANGER |
M059J | - | Growth Inhibition Assay | - | IC50=5.2576 μM | SANGER |
M14 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
M14 | - | Growth Inhibition Assay | - | IC50=2.66993 μM | SANGER |
MALME-3M | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.32 μM | 22435669 |
MC116 | - | Growth Inhibition Assay | - | IC50=1.13621 μM | SANGER |
MCF10A | 6.2 μM | Growth Inhibition Assay | 48 h | GI50=9.6 μM | 22435669 |
MCF7 | 10 μM | Function Assay | 8 h | Induction of tubulin hyperacetylation | 18269226 |
MCF7 | - | Growth Inhibition Assay | 48 h | GI=0.45 μM | 24119555 |
MCF7 | - | Growth Inhibition Assay | - | IC50=5.00738 μM | SANGER |
MC-IXC | - | Growth Inhibition Assay | - | IC50=1.17881 μM | SANGER |
MCR5-SV2 | 10 μM | Growth Inhibition Assay | 72 h | GI50=2.1 μM | 21080647 |
MDA-MB-175-VII | - | Growth Inhibition Assay | - | IC50=5.64041 μM | SANGER |
MDA-MB-231 | 10 μM | Kinase Assay | 30 min | Inhibition of HDAC2a | 23493449 |
MDA-MB-231 | 1 μM | Kinase Assay | 24 h | Inhibition of HDAC6 assessed as acetylation levels of tubulin | 23493449 |
MDA-MB-231 | - | Growth Inhibition Assay | 48 h | IC50=0.16 μM | 24095016 |
MDA-MB-231 | 10 μM | Kinase Assay | 5 min | does not inhibit HDAC2a | 23493449 |
MDA-MB-231 | 1 μM | Kinase Assay | 24 h | does not inhibit HDAC6 assessed as acetylation levels of tubulin | 23493449 |
MDA-MB-231 | - | Growth Inhibition Assay | - | IC50=4.70243 μM | SANGER |
MDA-MB-231 CisR | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.61 μM | 23252603 |
MDA-MB-231 sens | - | Kinase Assay | 18 h | Inhibition of HDAC with IC50 of 0.61 μM | 23252603 |
MDA-MB-361 | - | Growth Inhibition Assay | - | IC50=1.73157 μM | SANGER |
MDA-MB-415 | - | Growth Inhibition Assay | - | IC50=5.92139 μM | SANGER |
MDA-MB-435 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.5 μM | 22435669 |
MDA-MB-435 | - | Growth Inhibition Assay | 48 h | GI=0.88 μM | 24119555 |
MDA-MB-453 | - | Growth Inhibition Assay | - | IC50=2.24275 μM | SANGER |
MDA-MB-468 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.63 μM | 22435669 |
ME-180 | - | Growth Inhibition Assay | - | IC50=9.06725 μM | SANGER |
MEF | 10 μM | Cytotoxic Assay | 72 h | IC50=4.4 μM | 23570542 |
MEG-01 | - | Growth Inhibition Assay | - | IC50=3.06164 μM | SANGER |
MEL-HO | - | Growth Inhibition Assay | - | IC50=1.00582 μM | SANGER |
MEL-JUSO | - | Growth Inhibition Assay | - | IC50=3.89153 μM | SANGER |
Mewo | - | Growth Inhibition Assay | - | IC50=4.81747 μM | SANGER |
MFE-280 | - | Growth Inhibition Assay | - | IC50=9.72785 μM | SANGER |
MG-63 | - | Growth Inhibition Assay | - | IC50=7.41849 μM | SANGER |
MGC803 | - | Growth Inhibition Assay | 72 h | GI90=10.8 μM | 23061376 |
MHH-ES-1 | - | Growth Inhibition Assay | - | IC50=1.70435 μM | SANGER |
MHH-NB-11 | - | Growth Inhibition Assay | - | IC50=1.28329 μM | SANGER |
MHH-PREB-1 | - | Growth Inhibition Assay | - | IC50=294.53 nM | SANGER |
Mia Paca2 | 50 μM | Cytotoxic Assay | 72h | IC50=1.1 μM | 18494463 |
MIA-PaCa-2 | - | Growth Inhibition Assay | - | IC50=949.12 nM | SANGER |
MKN28 | - | Growth Inhibition Assay | - | IC50=2.59037 μM | SANGER |
MKN45 | - | Cytotoxic Assay | 12 h | IC50=1.25 μM | 24766560 |
MKN45 | - | Growth Inhibition Assay | - | IC50=4.57732 μM | SANGER |
MKN7 | - | Growth Inhibition Assay | - | IC50=5.988 μM | SANGER |
ML-2 | - | Growth Inhibition Assay | - | IC50=1.00407 μM | SANGER |
MLMA | - | Growth Inhibition Assay | - | IC50=2.96717 μM | SANGER |
MMAC-SF | - | Growth Inhibition Assay | - | IC50=4.26859 μM | SANGER |
MN-60 | - | Growth Inhibition Assay | - | IC50=1.0268 μM | SANGER |
MOLT-13 | - | Growth Inhibition Assay | - | IC50=738.98 nM | SANGER |
MOLT-16 | - | Growth Inhibition Assay | - | IC50=1.29797 μM | SANGER |
MOLT4 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.4 μM | 22435669 |
MOLT-4 | - | Growth Inhibition Assay | - | IC50=787.46 nM | SANGER |
MONE1 | - | Cytotoxic Assay | 12 h | IC50=1.18 μM | 24766560 |
Mo-T | - | Growth Inhibition Assay | - | IC50=2.50927 μM | SANGER |
MPP-89 | - | Growth Inhibition Assay | - | IC50=7.59729 μM | SANGER |
MS-1 | - | Growth Inhibition Assay | - | IC50=1.00617 μM | SANGER |
MSTO-211H | - | Growth Inhibition Assay | - | IC50=6.72233 μM | SANGER |
MUF | 100 μM | Growth Inhibition Assay | 48 h | Growth inhibition at 0.05 to 100 uM | 20143840 |
MV-4-11 | - | Growth Inhibition Assay | - | IC50=659.1 nM | SANGER |
MZ1-PC | - | Growth Inhibition Assay | - | IC50=24.6759 μM | SANGER |
MZ2-MEL | - | Growth Inhibition Assay | - | IC50=3.47681 μM | SANGER |
NB10 | - | Growth Inhibition Assay | - | IC50=751.92 nM | SANGER |
NB12 | - | Growth Inhibition Assay | - | IC50=2.7171 μM | SANGER |
NB13 | - | Growth Inhibition Assay | - | IC50=1.05501 μM | SANGER |
NB14 | - | Growth Inhibition Assay | - | IC50=696.95 nM | SANGER |
NB17 | - | Growth Inhibition Assay | - | IC50=2.38243 μM | SANGER |
NB4 | - | - | 48h | IC50=0.6 μM | 18723349 |
NB4 | 5 μM | Function Assay | 24 h | Cell cycle arrest assessed as increase in accumulation at pre-G1 phase | 20491440 |
NB4 | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as increase in acetylate tubulin level | 20491440 |
NB4 | 5 μM | Function Assay | 24 h | Induction of p21WAF1/CIP1 expression | 20491440 |
NB4 | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as increase in histone H3 acetylation | 20491440 |
NB5 | - | Growth Inhibition Assay | - | IC50=1.19856 μM | SANGER |
NB6 | - | Growth Inhibition Assay | - | IC50=1.91298 μM | SANGER |
NB69 | - | Growth Inhibition Assay | - | IC50=411.71 nM | SANGER |
NB7 | - | Growth Inhibition Assay | - | IC50=345.74 nM | SANGER |
NBsusSR | - | Growth Inhibition Assay | - | IC50=1.05166 μM | SANGER |
NCI60 | - | Cytotoxic Assay | 48 h | GI=0.53 μM | 24015327 |
NCI-ADR-RES | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.16 μM | 22435669 |
NCI-H1048 | - | Growth Inhibition Assay | - | IC50=2.55025 μM | SANGER |
NCI-H1092 | - | Growth Inhibition Assay | - | IC50=1.15406 μM | SANGER |
NCI-H1155 | - | Growth Inhibition Assay | - | IC50=2.36725 μM | SANGER |
NCI-H1299 | - | Growth Inhibition Assay | - | IC50=5.46335 μM | SANGER |
NCI-H1304 | - | Growth Inhibition Assay | - | IC50=20.7501 μM | SANGER |
NCI-H1355 | - | Growth Inhibition Assay | - | IC50=3.00796 μM | SANGER |
NCI-H1395 | - | Growth Inhibition Assay | - | IC50=10.178 μM | SANGER |
NCI-H1437 | - | Growth Inhibition Assay | - | IC50=2.41873 μM | SANGER |
NCI-H1563 | - | Growth Inhibition Assay | - | IC50=3.33018 μM | SANGER |
NCI-H1573 | - | Growth Inhibition Assay | - | IC50=9.10532 μM | SANGER |
NCI-H1581 | - | Growth Inhibition Assay | - | IC50=3.84488 μM | SANGER |
NCI-H1623 | - | Growth Inhibition Assay | - | IC50=7.14072 μM | SANGER |
NCI-H1648 | - | Growth Inhibition Assay | - | IC50=4.72273 μM | SANGER |
NCI-H1650 | - | Growth Inhibition Assay | - | IC50=30.1924 μM | SANGER |
NCI-H1651 | - | Growth Inhibition Assay | - | IC50=3.24644 μM | SANGER |
NCI-H1666 | - | Growth Inhibition Assay | - | IC50=2.28111 μM | SANGER |
NCI-H1693 | - | Growth Inhibition Assay | - | IC50=12.5816 μM | SANGER |
NCI-H1703 | - | Growth Inhibition Assay | - | IC50=5.35826 μM | SANGER |
NCI-H1755 | - | Growth Inhibition Assay | - | IC50=16.573 μM | SANGER |
NCI-H1770 | - | Growth Inhibition Assay | - | IC50=1.48536 μM | SANGER |
NCI-H1792 | - | Growth Inhibition Assay | - | IC50=4.76107 μM | SANGER |
NCI-H1838 | - | Growth Inhibition Assay | - | IC50=8.25781 μM | SANGER |
NCI-H2029 | - | Growth Inhibition Assay | - | IC50=19.6021 μM | SANGER |
NCI-H2030 | - | Growth Inhibition Assay | - | IC50=6.91226 μM | SANGER |
NCI-H2052 | - | Growth Inhibition Assay | - | IC50=10.1882 μM | SANGER |
NCI-H2087 | - | Growth Inhibition Assay | - | IC50=9.67352 μM | SANGER |
NCI-H209 | - | Growth Inhibition Assay | - | IC50=729.9 nM | SANGER |
NCI-H2122 | - | Growth Inhibition Assay | 72 h | IC50=7.5 μM | 20143778 |
NCI-H2122 | - | Growth Inhibition Assay | - | IC50=3.41312 μM | SANGER |
NCI-H2126 | - | Growth Inhibition Assay | - | IC50=2.60984 μM | SANGER |
NCI-H2170 | - | Growth Inhibition Assay | - | IC50=2.50549 μM | SANGER |
NCI-H2228 | - | Growth Inhibition Assay | - | IC50=34.3605 μM | SANGER |
NCI-H226 | - | Growth Inhibition Assay | 48 h | IC50=2.6 μM | 15715470 |
NCI-H226 | - | Growth Inhibition Assay | - | IC50=17.9345 μM | SANGER |
NCI-H2291 | - | Growth Inhibition Assay | - | IC50=49.8301 μM | SANGER |
NCI-H23 | - | Growth Inhibition Assay | 48 h | GI50=0.92 μM | 16723227 |
NCI-H23 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1 μM | 22435669 |
NCI-H23 | - | Growth Inhibition Assay | - | IC50=1.54645 μM | SANGER |
NCI-H2347 | - | Growth Inhibition Assay | - | IC50=23.2674 μM | SANGER |
NCI-H2405 | - | Growth Inhibition Assay | - | IC50=12.2036 μM | SANGER |
NCI-H2452 | - | Growth Inhibition Assay | - | IC50=10.16 μM | SANGER |
NCI-H28 | - | Growth Inhibition Assay | - | IC50=8.05963 μM | SANGER |
NCI-H292 | - | Growth Inhibition Assay | - | IC50=2.86596 μM | SANGER |
NCI-H322M | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.79 μM | 22435669 |
NCI-H358 | - | Growth Inhibition Assay | 72 h | IC50=2.5 μM | 20143778 |
NCI-H441 | - | Growth Inhibition Assay | - | IC50=16.0039 μM | SANGER |
NCI-H446 | - | Growth Inhibition Assay | - | IC50=2.04599 μM | SANGER |
NCI-H460 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.79 μM | 22435669 |
NCI-H510A | - | Growth Inhibition Assay | - | IC50=2.64426 μM | SANGER |
NCI-H520 | - | Growth Inhibition Assay | - | IC50=22.7611 μM | SANGER |
NCI-H522 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.5 μM | 22435669 |
NCI-H526 | - | Growth Inhibition Assay | - | IC50=1.08291 μM | SANGER |
NCI-H596 | - | Growth Inhibition Assay | - | IC50=23.9055 μM | SANGER |
NCI-H630 | - | Growth Inhibition Assay | - | IC50=4.78081 μM | SANGER |
NCI-H650 | - | Growth Inhibition Assay | - | IC50=3.64287 μM | SANGER |
NCI-H661 | - | Growth Inhibition Assay | - | IC50=2.64085 μM | SANGER |
NCI-H69 | - | Cytotoxic Assay | 72 h | IC50=2.06 μM | 19093884 |
NCI-H69 | - | Growth Inhibition Assay | - | IC50=1.34112 μM | SANGER |
NCI-H720 | - | Growth Inhibition Assay | - | IC50=560.18 nM | SANGER |
NCI-H727 | - | Growth Inhibition Assay | - | IC50=47.2451 μM | SANGER |
NCI-H747 | - | Growth Inhibition Assay | - | IC50=10.8746 μM | SANGER |
NCI-H810 | - | Growth Inhibition Assay | - | IC50=3.04823 μM | SANGER |
NCI-H82 | - | Growth Inhibition Assay | - | IC50=26.4288 μM | SANGER |
NCI-N87 | - | Growth Inhibition Assay | - | IC50=4.50868 μM | SANGER |
NCI-SNU-1 | - | Growth Inhibition Assay | - | IC50=1.02331 μM | SANGER |
NCI-SNU-5 | - | Growth Inhibition Assay | - | IC50=7.02159 μM | SANGER |
NEC8 | - | Growth Inhibition Assay | - | IC50=289.38 nM | SANGER |
NH-12 | - | Growth Inhibition Assay | - | IC50=1.72691 μM | SANGER |
NKM-1 | - | Growth Inhibition Assay | - | IC50=544.27 nM | SANGER |
NMC-G1 | - | Growth Inhibition Assay | - | IC50=37.0529 μM | SANGER |
no-10 | - | Growth Inhibition Assay | - | IC50=12.1217 μM | SANGER |
no-11 | - | Growth Inhibition Assay | - | IC50=9.26028 μM | SANGER |
NOMO-1 | - | Growth Inhibition Assay | - | IC50=2.19317 μM | SANGER |
NOS-1 | - | Growth Inhibition Assay | - | IC50=1.41194 μM | SANGER |
NTERA-S-cl-D1 | - | Growth Inhibition Assay | - | IC50=1.31761 μM | SANGER |
NUGC3 | 5 μM | Growth Inhibition Assay | 24 h | GI50=2.79 μM | 17904843 |
NUGC3 | - | Growth Inhibition Assay | - | GI50=2.94 μM | 20850971 |
NUGC3 | 10 μM | Growth Inhibition Assay | - | GI=2.94 μM | 23163332 |
NUGC-3 | - | Growth Inhibition Assay | - | IC50=4.25505 μM | SANGER |
NY | - | Growth Inhibition Assay | - | IC50=49.3908 μM | SANGER |
OAW-28 | - | Growth Inhibition Assay | - | IC50=4.58398 μM | SANGER |
OAW-42 | - | Growth Inhibition Assay | - | IC50=2.33416 μM | SANGER |
OC-314 | - | Growth Inhibition Assay | - | IC50=2.23259 μM | SANGER |
OCI-AML2 | - | Growth Inhibition Assay | - | IC50=4.65238 μM | SANGER |
OCUB-M | - | Growth Inhibition Assay | - | IC50=3.54665 μM | SANGER |
OE19 | - | Growth Inhibition Assay | - | IC50=8.76262 μM | SANGER |
OE33 | - | Growth Inhibition Assay | - | IC50=4.87713 μM | SANGER |
OMC-1 | - | Growth Inhibition Assay | - | IC50=6.85402 μM | SANGER |
ONS-76 | - | Growth Inhibition Assay | - | IC50=1.82897 μM | SANGER |
OS-RC-2 | - | Growth Inhibition Assay | - | IC50=1.87151 μM | SANGER |
OVCAR3 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
OVCAR-3 | - | Growth Inhibition Assay | - | IC50=7.21133 μM | SANGER |
OVCAR4 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=4 μM | 22435669 |
OVCAR-4 | - | Growth Inhibition Assay | - | IC50=3.92889 μM | SANGER |
OVCAR5 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.79 μM | 22435669 |
OVCAR-5 | - | Growth Inhibition Assay | - | IC50=576.11 nM | SANGER |
OVCAR8 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.5 μM | 22435669 |
OVCAR-8 | - | Growth Inhibition Assay | - | IC50=1.54477 μM | SANGER |
P12-ICHIKAWA | - | Growth Inhibition Assay | - | IC50=596.51 nM | SANGER |
P30-OHK | - | Growth Inhibition Assay | - | IC50=835.7 nM | SANGER |
PA-1 | - | Growth Inhibition Assay | - | IC50=286.26 nM | SANGER |
Panc 04.03 | 50 μM | Cytotoxic Assay | 72h | IC50=1.2 μM | 18494463 |
PANC-03-27 | - | Growth Inhibition Assay | - | IC50=4.99962 μM | SANGER |
PANC-08-13 | - | Growth Inhibition Assay | - | IC50=3.79602 μM | SANGER |
PANC1 | 1 μM | Growth Inhibition Assay | - | IC50=0.45 μM | 17588744 |
PANC1 | 1 μM | Function Assay | 24 h | Increase in p21WAF1/CIP1 gene expression | 17588744 |
PANC1 | 1 μM | Function Assay | 24 h | Increase in p27kip1 gene expression | 17588744 |
PANC1 | 1 μM | Function Assay | 24 h | does not increase in p27kip1 gene expression | 17588744 |
PANC1 | 1 μM | Function Assay | 48 h | does not increase in p27kip1 gene expression | 17588744 |
PANC-10-05 | - | Growth Inhibition Assay | - | IC50=8.37047 μM | SANGER |
PC-14 | - | Growth Inhibition Assay | - | IC50=2.8051 μM | SANGER |
PC3 | - | Growth Inhibition Assay | 21 h | GI50=0.71 μM | 17662606 |
PC-3 | - | Growth Inhibition Assay | - | IC50=3.03874 μM | SANGER |
PFSK-1 | - | Growth Inhibition Assay | - | IC50=1.8037 μM | SANGER |
Primary bronchial epithelial cell | 1 μM | Kinase Assay | 24 h | Inhibition of HDAC7 assessed as induction of mutant Fdelta508 CFTR protein apical surface localization | 19966789 |
Primary bronchial epithelial cell | 5 μM | Kinase Assay | 24 h | Inhibition of HDAC assessed as induction of mutant Fdelta508 CFTR protein apical surface localization | 19966789 |
Primary bronchial epithelial cell | 1 μM | Kinase Assay | 96 h | Inhibition of HDAC7 assessed as increase in short circuit currents | 19966789 |
PSN1 | - | Growth Inhibition Assay | - | IC50=2.28913 μM | SANGER |
PT45 | - | Growth Inhibition Assay | - | IC50=4 μM | 17588744 |
QIMR-WIL | - | Growth Inhibition Assay | - | IC50=862.03 nM | SANGER |
Ramos-2G6-4C10 | - | Growth Inhibition Assay | - | IC50=1.99493 μM | SANGER |
RAW264.7 | 10 μM | Function Assay | 24h | Inhibition of LPS-stimulated TNFalpha production with IC50 of 0.76 μM | 17477518 |
RAW264.7 | 10 μM | Function Assay | 24h | Inhibition of LPS-stimulated NO production with IC50 of 1.88 μM | 17477518 |
RAW264.7 | 2 μM | Function Assay | 3.5 h | Antimalarial activity against Plasmodium falciparum infected with IC50 of 0.11 μM | 18644969 |
RCC10RGB | - | Growth Inhibition Assay | - | IC50=21.2829 μM | SANGER |
RCM-1 | - | Growth Inhibition Assay | - | IC50=1.12102 μM | SANGER |
RD | - | Growth Inhibition Assay | - | IC50=974.45 nM | SANGER |
RERF-LC-MS | - | Growth Inhibition Assay | - | IC50=5.06903 μM | SANGER |
RH-1 | - | Growth Inhibition Assay | - | IC50=3.10278 μM | SANGER |
RH-18 | - | Growth Inhibition Assay | - | IC50=2.35022 μM | SANGER |
RKO | - | Growth Inhibition Assay | - | IC50=3.30757 μM | SANGER |
RKOp21 | - | Cytotoxic Assay | 72 h | IC50=1.76 μM | 17691763 |
RMG-I | - | Growth Inhibition Assay | - | IC50=3.02592 μM | SANGER |
RO82-W-1 | - | Growth Inhibition Assay | - | IC50=13.0649 μM | SANGER |
RPMI-2650 | - | Growth Inhibition Assay | - | IC50=2.64143 μM | SANGER |
RPMI-7951 | - | Growth Inhibition Assay | - | IC50=3.74723 μM | SANGER |
RPMI-8226 | - | Growth Inhibition Assay | - | IC50=678.18 nM | SANGER |
RPMI-8866 | - | Growth Inhibition Assay | - | IC50=813.67 nM | SANGER |
RS4-11 | - | Growth Inhibition Assay | - | IC50=832.45 nM | SANGER |
RT-112 | - | Growth Inhibition Assay | - | IC50=1.59284 μM | SANGER |
RVH-421 | - | Growth Inhibition Assay | - | IC50=5.49908 μM | SANGER |
RXF393 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
RXF393 | - | Growth Inhibition Assay | - | IC50=3.53294 μM | SANGER |
RXF-631L | - | Growth Inhibition Assay | 48 h | IC50=2 μM | 15715470 |
S-117 | - | Growth Inhibition Assay | - | IC50=8.25353 μM | SANGER |
S2 | 0.1-10 μM | Kinase Assay | 1 h | Inhibition of Plasmodium falciparum HDAC1 expressed with IC50 of 0.059 μM | 19317450 |
Saos2 | - | Cytotoxic Assay | 72 h | IC50=2.3 μM | 17691763 |
Saos-2 | - | Growth Inhibition Assay | - | IC50=9.52195 μM | SANGER |
SAS | - | Growth Inhibition Assay | - | IC50=1.04081 μM | SANGER |
SBC-1 | - | Growth Inhibition Assay | - | IC50=793.84 nM | SANGER |
SBC-5 | - | Growth Inhibition Assay | - | IC50=2.06147 μM | SANGER |
SC9 | - | Growth Inhibition Assay | 48 h | IC50=0.606 μM | 17507219 |
SCC15 | - | Growth Inhibition Assay | 72 h | IC50=2.49 μM | 20143778 |
SCC-15 | - | Growth Inhibition Assay | - | IC50=1.93819 μM | SANGER |
SCC25 | - | Growth Inhibition Assay | 72 h | IC50=1.93 μM | 20143778 |
SCC-25 | - | Growth Inhibition Assay | - | IC50=4.35819 μM | SANGER |
SCC4 | 1 μM | Kinase Assay | 24h | Inhibition of HDAC assessed as increase in tubulin acetylation | 20452225 |
SCC4 | 1 μM | Kinase Assay | 24h | Inhibition of HDAC assessed as increase in histone acetylation | 20452225 |
SCC4 | 1 μM | Function Assay | 5 min | Agonist activity at VDR assessed as induction of CYP24 gene expression | 20452225 |
SCC4 | 1 μM | Function Assay | 10 min | has no agonist activity at VDR assessed as induction of CYP24 gene expression | 20452225 |
SCC-4 | - | Growth Inhibition Assay | - | IC50=2.63012 μM | SANGER |
SCC-9 | - | Growth Inhibition Assay | - | IC50=9.71816 μM | SANGER |
SCH | - | Growth Inhibition Assay | - | IC50=4.15743 μM | SANGER |
SF126 | - | Growth Inhibition Assay | - | IC50=10.4727 μM | SANGER |
Sf21 | - | Kinase Assay | 3 h | Inhibition of Flag tagged human recombinant HDAC8 expressed with IC50 of 1.2 μM | 21080629 |
SF268 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.6 μM | 22435669 |
SF268 | - | Growth Inhibition Assay | - | IC50=3.04523 μM | SANGER |
SF295 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.6 μM | 22435669 |
SF295 | - | Growth Inhibition Assay | - | IC50=1.06624 μM | SANGER |
SF539 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=2 μM | 22435669 |
SF539 | - | Growth Inhibition Assay | - | IC50=5.26632 μM | SANGER |
SGC7901 | - | Growth Inhibition Assay | 72 h | GI90=9.4 μM | 23061376 |
SH-4 | - | Growth Inhibition Assay | - | IC50=9.49364 μM | SANGER |
SHP-77 | - | Growth Inhibition Assay | - | IC50=7.13952 μM | SANGER |
SHSY5Y | 10 μM | Kinase Assay | 48 h | Inhibition of HDAC with IC50 of 0.5 μM | 19344175 |
SHSY5Y | 10 μM | Cytotoxic Assay | 48 h | IC50=2 μM | 19344175 |
SiHa | - | Growth Inhibition Assay | - | IC50=7.83707 μM | SANGER |
SJSA-1 | - | Growth Inhibition Assay | - | IC50=6.56347 μM | SANGER |
SKBR3 | - | Growth Inhibition Assay | - | IC50=0.8 μM | 18247554 |
SKBR3 | - | Cytotoxic Assay | 72 h | Cytotoxicity against human SKBR3 cells overexpressing HER2 with IC50 of 2.6 μM | 21080629 |
SKG-IIIa | - | Growth Inhibition Assay | - | IC50=1.23464 μM | SANGER |
SKHEP1 | - | Growth Inhibition Assay | 72 h | IC50=3.46 μM | 20143778 |
SKHEP1 | - | Growth Inhibition Assay | 72 h | GI90=17 μM | 23061376 |
SK-HEP-1 | - | Growth Inhibition Assay | - | IC50=2.74391 μM | SANGER |
SK-LU-1 | - | Growth Inhibition Assay | - | IC50=23.0718 μM | SANGER |
SK-MEL-1 | - | Growth Inhibition Assay | - | IC50=10.7838 μM | SANGER |
SK-MEL-2 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1.3 μM | 22435669 |
SK-MEL-2 | - | Growth Inhibition Assay | - | IC50=809.44 nM | SANGER |
SK-MEL-28 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1 μM | 22435669 |
SK-MEL-28 | - | Growth Inhibition Assay | - | IC50=10.0193 μM | SANGER |
SK-MEL-3 | - | Growth Inhibition Assay | - | IC50=3.82841 μM | SANGER |
SK-MEL-30 | - | Growth Inhibition Assay | - | IC50=11.4079 μM | SANGER |
SK-MEL-5 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.63 μM | 22435669 |
SKMES1 | - | Cytotoxic Assay | 72 h | IC50=2.42 μM | 19093884 |
SK-MES-1 | - | Growth Inhibition Assay | - | IC50=7.05427 μM | SANGER |
SK-N-AS | - | Growth Inhibition Assay | - | IC50=988.1 nM | SANGER |
SK-N-DZ | - | Growth Inhibition Assay | - | IC50=900.43 nM | SANGER |
SK-NEP-1 | - | Growth Inhibition Assay | - | IC50=1.41693 μM | SANGER |
SK-N-FI | - | Growth Inhibition Assay | - | IC50=4.94421 μM | SANGER |
SKOV3 | - | Cytotoxic Assay | 72 h | Cytotoxicity against human SKOV3 cells overexpressing HER2 with IC50 of 2.2 μM | 21080629 |
SKOV3 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=1 μM | 22435669 |
SK-OV-3 | - | Cytotoxic Assay | 72 h | IC50=2.2 μM | 17691763 |
SK-PN-DW | - | Growth Inhibition Assay | - | IC50=17.4201 μM | SANGER |
SK-UT-1 | - | Growth Inhibition Assay | - | IC50=5.27751 μM | SANGER |
SMMC7721 | - | Growth Inhibition Assay | 72 h | GI90=20 μM | 23061376 |
SN12C | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=2 μM | 22435669 |
SN12C | - | Growth Inhibition Assay | - | IC50=2.43214 μM | SANGER |
SNB19 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.63 μM | 22435669 |
SNB75 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.79 μM | 22435669 |
SNB75 | - | Growth Inhibition Assay | - | IC50=15.0729 μM | SANGER |
SNB78 | - | Growth Inhibition Assay | - | EC50=16 μM | 18247554 |
SNB78 | - | Growth Inhibition Assay | 48 h | GI50=16 μM | 19419205 |
SNB-78 | - | Growth Inhibition Assay | 48 h | IC50=16 μM | 15715470 |
SNU-387 | - | Growth Inhibition Assay | - | IC50=7.85347 μM | SANGER |
SNU-423 | - | Growth Inhibition Assay | - | IC50=1.75827 μM | SANGER |
SNU-449 | - | Growth Inhibition Assay | - | IC50=2.89182 μM | SANGER |
SNU-C2B | - | Growth Inhibition Assay | - | IC50=4.24769 μM | SANGER |
SQ20B | - | Growth Inhibition Assay | - | IC50=3 μM | 18247554 |
SR | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.4 μM | 22435669 |
ST14A | 5 nM | Function Assay | 72 h | Increase in REST/NRSF mRNA expression | 17565993 |
ST14A | 5 nM | Function Assay | 72 h | Increase in E2F1 mRNA expression | 17565993 |
St4 | - | Growth Inhibition Assay | - | EC50=5.2 μM | 18247554 |
St-4 | - | Growth Inhibition Assay | 48 h | IC50=5.2 μM | 15715470 |
SU 86.86 | 50 μM | Cytotoxic Assay | 72h | IC50=1.3 μM | 18494463 |
SW1088 | - | Growth Inhibition Assay | - | IC50=5.02944 μM | SANGER |
SW1116 | - | Growth Inhibition Assay | - | IC50=3.46269 μM | SANGER |
SW13 | - | Growth Inhibition Assay | - | IC50=3.07847 μM | SANGER |
SW1417 | - | Growth Inhibition Assay | - | IC50=25.2498 μM | SANGER |
SW1573 | - | Growth Inhibition Assay | - | IC50=2.96082 μM | SANGER |
SW1710 | - | Growth Inhibition Assay | - | IC50=5.41554 μM | SANGER |
SW1783 | - | Growth Inhibition Assay | - | IC50=14.2391 μM | SANGER |
SW48 | - | Growth Inhibition Assay | - | IC50=3.65657 μM | SANGER |
SW620 | - | Cytotoxic Assay | 48 h | GI=0.54 μM | 24015327 |
SW620 | - | Growth Inhibition Assay | - | IC50=1.29018 μM | SANGER |
SW626 | - | Growth Inhibition Assay | - | IC50=1.94899 μM | SANGER |
SW684 | - | Growth Inhibition Assay | - | IC50=9.46116 μM | SANGER |
SW756 | - | Growth Inhibition Assay | - | IC50=3.29629 μM | SANGER |
SW780 | - | Growth Inhibition Assay | - | IC50=4.85766 μM | SANGER |
SW837 | - | Growth Inhibition Assay | - | IC50=5.37878 μM | SANGER |
SW872 | - | Growth Inhibition Assay | - | IC50=15.2218 μM | SANGER |
SW900 | - | Growth Inhibition Assay | - | IC50=6.76221 μM | SANGER |
SW948 | - | Growth Inhibition Assay | - | IC50=2.18456 μM | SANGER |
SW954 | - | Growth Inhibition Assay | - | IC50=863.16 nM | SANGER |
SW962 | - | Growth Inhibition Assay | - | IC50=4.78011 μM | SANGER |
SW982 | - | Growth Inhibition Assay | - | IC50=3.80551 μM | SANGER |
T24 | - | Kinase Assay | 3 h | Induction of histone H3 acetylation with EC50 of 0.12 μM | 19084395 |
T24 | - | Kinase Assay | 3 h | Induction of alpha tubulin acetylation with EC50 of 0.25 μM | 19084395 |
T-24 | - | Growth Inhibition Assay | - | IC50=3.1507 μM | SANGER |
T47D | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.5 μM | 22435669 |
T47D | - | Growth Inhibition Assay | - | IC50=3.23627 μM | SANGER |
T98G | - | Growth Inhibition Assay | - | IC50=4.22157 μM | SANGER |
TCCSUP | - | Growth Inhibition Assay | - | IC50=1.72829 μM | SANGER |
TE-1 | - | Growth Inhibition Assay | - | IC50=791.1 nM | SANGER |
TE-10 | - | Growth Inhibition Assay | - | IC50=3.9201 μM | SANGER |
TE-11 | - | Growth Inhibition Assay | - | IC50=7.15184 μM | SANGER |
TE-12 | - | Growth Inhibition Assay | - | IC50=16.1873 μM | SANGER |
TE-5 | - | Growth Inhibition Assay | - | IC50=7.02881 μM | SANGER |
TE-6 | - | Growth Inhibition Assay | - | IC50=4.93977 μM | SANGER |
TE-8 | - | Growth Inhibition Assay | - | IC50=2.15765 μM | SANGER |
TE-9 | - | Growth Inhibition Assay | - | IC50=6.89847 μM | SANGER |
TGBC11TKB | - | Growth Inhibition Assay | - | IC50=2.47177 μM | SANGER |
TGBC1TKB | - | Growth Inhibition Assay | - | IC50=8.73535 μM | SANGER |
TGBC24TKB | - | Growth Inhibition Assay | - | IC50=14.9539 μM | SANGER |
TI-73 | - | Growth Inhibition Assay | - | IC50=1.5906 μM | SANGER |
TK10 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.63 μM | 22435669 |
TK10 | - | Growth Inhibition Assay | - | IC50=3.13724 μM | SANGER |
TSGH | - | Cytotoxic Assay | 12 h | IC50=2.09 μM | 24766560 |
TYK-nu | - | Growth Inhibition Assay | - | IC50=1.49851 μM | SANGER |
U031 | - | Growth Inhibition Assay | - | IC50=15.8028 μM | SANGER |
U-118-MG | - | Growth Inhibition Assay | - | IC50=23.7217 μM | SANGER |
U251 | - | Cytotoxic Assay | 48 h | GI=1.53 μM | 24015327 |
U251 | - | Growth Inhibition Assay | - | IC50=5.39096 μM | SANGER |
U-266 | - | Growth Inhibition Assay | - | IC50=2.77121 μM | SANGER |
U-2-OS | - | Growth Inhibition Assay | - | IC50=1.07911 μM | SANGER |
U87MG | - | Cytotoxic Assay | 72 h | IC50=11 μM | 17691763 |
U-87-MG | - | Growth Inhibition Assay | - | IC50=20.6413 μM | SANGER |
U937 | 5 μM | Function Assay | 24 h | Cell cycle arrest by accumulation at S/G2/M phase | 17004718 |
U937 | 5 μM | Function Assay | 24 h | Increase in histone H3 acetylation | 17447750 |
U937 | 1 μM | Function Assay | 24 h | Effect on alpha tubulin acetylation | 17447750 |
U937 | 5 μM | Function Assay | 24 h | Induction of histone H4 hyperacetylation | 18381238 |
U937 | 5 μM | Function Assay | 24 h | Induction of alpha tubulin hyperacetylation | 18381238 |
U937 | 5 μM | Function Assay | 24 h | Induction of p21 expression | 18381238 |
U937 | 5 μM | Function Assay | 24 h | Induction of apoptosis | 18381238 |
U937 | 5 μM | Function Assay | 24 h | Induction of granulocytic differentiation | 18381238 |
U937 | 5 μM | Kinase Assay | 24 h | Inhibition of human HDAC1 | 18381238 |
U937 | 5 μM | Kinase Assay | 24 h | Inhibition of human HDAC4 | 18381238 |
U937 | - | Growth Inhibition Assay | 72 h | GI50=0.39 μM | 20884208 |
U937 | 5 μM | Kinase Assay | 24 h | Inhibition of histone acetyltransferase assessed as increase of acetylation of histone H3 at K9 | 21292492 |
U937 | 5 μM | Kinase Assay | 24 h | Inhibition of histone acetyltransferase assessed as increase of acetylation of histone H3 at K18 | 21292492 |
U937 | 5 μM | Kinase Assay | 24 h | Inhibition of histone acetyltransferase assessed as increase of pan-acetylated histone H4 level | 21292492 |
U937 | 5 μM | Kinase Assay | 15 min | Inhibition of histone acetyltransferase assessed as increase of histone H3 acetylation level | 21292492 |
U937 | 5 μM | Kinase Assay | 24 h | has no effect on alpha tubulin acetylation | 17447750 |
U937 | 1 μM | Kinase Assay | 24 h | has no effect on alpha tubulin acetylation | 17447750 |
UACC257 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.5 μM | 22435669 |
UACC-257 | - | Growth Inhibition Assay | - | IC50=5.02845 μM | SANGER |
UACC62 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.4 μM | 22435669 |
UACC-62 | - | Growth Inhibition Assay | - | IC50=42.5505 μM | SANGER |
UACC-893 | - | Growth Inhibition Assay | - | IC50=23.1038 μM | SANGER |
UM-UC-3 | - | Growth Inhibition Assay | - | IC50=5.62651 μM | SANGER |
UO31 | 6.2 μM | Growth Inhibition Assay | 72 h | GI50=0.5 μM | 22435669 |
VA-ES-BJ | - | Growth Inhibition Assay | - | IC50=1.32477 μM | SANGER |
Vero | - | Growth Inhibition Assay | 72 h | IC50=0.9 μM | 23786452 |
VM-CUB-1 | - | Growth Inhibition Assay | - | IC50=1.19108 μM | SANGER |
VMRC-RCZ | - | Growth Inhibition Assay | - | IC50=36.3022 μM | SANGER |
WM-115 | - | Growth Inhibition Assay | - | IC50=3.78195 μM | SANGER |
YAPC | - | Growth Inhibition Assay | - | IC50=33.7648 μM | SANGER |
YH-13 | - | Growth Inhibition Assay | - | IC50=1.49894 μM | SANGER |
YKG-1 | - | Growth Inhibition Assay | - | IC50=2.45437 μM | SANGER |
ZR-75-30 | - | Growth Inhibition Assay | - | IC50=19.0968 μM | SANGER |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00771472 | Lymphoma | Phase 1 | Completed | - | - |
NCT00771472 | - | - | Completed | - | - |
NCT01064921 | Stage III Squamous Cell Carcin... more >>oma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Collapse << | Phase 1 | Completed | - | United States, Ohio ... more >> The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Collapse << |
NCT00731731 | Adult Giant Cell Glioblastoma ... more >> Adult Glioblastoma Adult Gliosarcoma Cognitive Side Effects of Cancer Therapy Collapse << | Phase 1 Phase 2 | Active, not recruiting | - | - |
NCT01567709 | Adult B Acute Lymphoblastic Le... more >>ukemia Adult T Acute Lymphoblastic Leukemia Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Chronic Lymphocytic Leukemia Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Hepatosplenic T-Cell Lymphoma Intraocular Lymphoma Lymphomatous Involvement of Non-Cutaneous Extranodal Site Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Nodal Marginal Zone Lymphoma Primary Cutaneous B-Cell Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides and Sezary Syndrome Recurrent Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Small Intestinal Lymphoma Splenic Marginal Zone Lymphoma T-Cell Large Granular Lymphocyte Leukemia Testicular Lymphoma Waldenstrom Macroglobulinemia Collapse << | Phase 1 | Completed | - | United States, California ... more >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Collapse << |
NCT00479232 | Leukemia, Myelocytic, Acute My... more >>elodysplastic Syndromes Myelodysplastic Syndromes Collapse << | Phase 1 | Completed | - | - |
NCT00731731 | - | - | Active, not recruiting | - | - |
NCT01267240 | Paranasal Sinus Squamous Cell ... more >>Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Stage IVA Hypopharyngeal Squamous Cell Carcinoma Stage IVA Laryngeal Squamous Cell Carcinoma Stage IVA Oral Cavity Squamous Cell Carcinoma Stage IVA Oropharyngeal Squamous Cell Carcinoma Stage IVB Hypopharyngeal Squamous Cell Carcinoma Stage IVB Laryngeal Squamous Cell Carcinoma Stage IVB Oral Cavity Squamous Cell Carcinoma Stage IVB Oropharyngeal Squamous Cell Carcinoma Stage IVC Hypopharyngeal Squamous Cell Carcinoma Stage IVC Laryngeal Squamous Cell Carcinoma Stage IVC Oral Cavity Squamous Cell Carcinoma Stage IVC Oropharyngeal Squamous Cell Carcinoma Collapse << | Phase 2 | Terminated(Study treatment did... more >> not show clinical activity.) Collapse << | - | United States, California ... more >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Contra Costa Regional Medical Center Martinez, California, United States, 94553-3156 Veterans Administration Hospital - Martinez Martinez, California, United States, 94553 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Canada, Alberta Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Health Sciences Centre-Corporate London, Ontario, Canada, N6A 4L6 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Collapse << |
NCT02538510 | Head and Neck Squamous Cell Ca... more >>rcinoma Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Recurrent Nasopharynx Carcinoma Recurrent Salivary Gland Carcinoma Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary Stage III Major Salivary Gland Carcinoma Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage III Nasopharyngeal Carcinoma Stage IV Nasopharyngeal Carcinoma Stage IVA Major Salivary Gland Carcinoma Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVB Major Salivary Gland Carcinoma Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVC Major Salivary Gland Carcinoma Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Collapse << | Phase 1 Phase 2 | Active, not recruiting | June 30, 2019 | United States, Washington ... more >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Collapse << |
NCT00128102 | Mesothelioma ... more >>Lung Cancer Collapse << | Phase 3 | Completed | - | - |
NCT01281176 | Adult Solid Neoplasm | Phase 1 | Active, not recruiting | - | United States, Illinois ... more >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Collapse << |
NCT01208454 | Localized Unresectable Neurobl... more >>astoma Recurrent Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Stage 4S Neuroblastoma Collapse << | Phase 1 | Completed | - | United States, California ... more >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 UCSF Medical Center-Parnassus San Francisco, California, United States, 94143 United States, Colorado Children's Hospital Colorado Aurora, Colorado, United States, 80045 United States, Georgia Children's Healthcare of Atlanta - Egleston Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Boston Children's Hospital Boston, Massachusetts, United States, 02115 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Texas Cook Children's Medical Center Fort Worth, Texas, United States, 76104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Collapse << |
NCT01267240 | - | - | Terminated(Study treatment did... more >> not show clinical activity.) Collapse << | - | - |
NCT00268385 | Adult Anaplastic Astrocytoma ... more >> Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Recurrent Adult Brain Neoplasm Collapse << | Phase 1 | Active, not recruiting | - | United States, Alabama ... more >> University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States, 35233 United States, California UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 UCSF Medical Center-Mount Zion San Francisco, California, United States, 94115 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 National Cancer Institute Neuro-Oncology Branch Bethesda, Maryland, United States, 20892 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Collapse << |
NCT00729118 | Multiple Myeloma ... more >> Plasma Cell Neoplasm Collapse << | Phase 1 | Active, not recruiting | December 31, 2018 | United States, Ohio ... more >> Ohio State University Columbus, Ohio, United States, 43210 Collapse << |
NCT00132067 | Primary Peritoneal Cavity Canc... more >>er Recurrent Ovarian Epithelial Cancer Collapse << | Phase 2 | Completed | - | United States, Pennsylvania ... more >> Gynecologic Oncology Group Philadelphia, Pennsylvania, United States, 19103 Collapse << |
NCT01492881 | Multiple Myeloma | Phase 2 | Withdrawn(Doxil is currently u... more >>navailable) Collapse << | January 2017 | United States, North Carolina ... more >> Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 Collapse << |
NCT01019850 | Neuroblastoma | Phase 1 | Completed | - | United States, California ... more >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Salter Packer Children's Hospital Palo Alto, California, United States, 94304 UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 United States, Georgia AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago, Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, Michigan C.S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 United States, Texas Cook Children's Medical Center - Fort Worth Fort Worth, Texas, United States, 76104 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 Collapse << |
NCT00731952 | Non Small Cell Lung Cancer | Phase 1 | Completed | - | United States, Virginia ... more >> University of Virginia Charlottesville, Virginia, United States, 22908 Collapse << |
NCT00798720 | Carcinoma, Non Small Cell Lung | Phase 2 | Completed | - | - |
NCT00857324 | Multiple Myeloma | Phase 1 Phase 2 | Terminated(The Phase I of the ... more >>study was completed, but Phase 2 has not been activated) Collapse << | - | Italy ... more >> Dipartimento Medicina Clinica e Sperimentale Padova, Italy, 35128 A.O.U. S. Giovanni Battista Torino, Italy, 10126 Policlinico Universitario di Udine Udine, Italy, 33100 Azienda Ospedaliera di Verona - Policlinico G.B. Rossi Verona, Italy, 37134 Collapse << |
NCT00798720 | - | - | Completed | - | - |
NCT00907738 | Advanced Cancer | Phase 2 | Completed | - | - |
NCT00907738 | - | - | Completed | - | - |
NCT00818649 | - | - | Terminated(Met protocol stop r... more >>ule [i.e., extreme toxicity]) Collapse << | - | - |
NCT00818649 | Leukemia Myel... more >>odysplastic Syndrome Collapse << | Phase 2 | Terminated(Met protocol stop r... more >>ule [i.e., extreme toxicity]) Collapse << | - | United States, Minnesota ... more >> Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States, 55455 Collapse << |
NCT00662311 | - | - | Terminated | - | - |
NCT00662311 | Stage IIIA Non-small Cell Lung... more >> Cancer Stage IIIB Non-small Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Terminated | - | United States, Washington ... more >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Collapse << |
NCT00810576 | - | - | Terminated(Terminated due to s... more >>low accrual.) Collapse << | - | - |
NCT03150329 | Grade 3a Follicular Lymphoma ... more >> Grade 3b Follicular Lymphoma Recurrent Classical Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Classical Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma Collapse << | Phase 1 | Recruiting | July 2019 | United States, California ... more >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Alex F. Herrera, MD 626-256-4673 ext 62405 aherrera@coh.org Principal Investigator: Alex F. Herrera, MD United States, New Jersey Hackensack University Medical Center Recruiting Hackensack, New Jersey, United States, 07601 Contact: Tatyana Feldman, MD 551-996-4469 Tatyana.Feldman@hackensackmeridian.org Principal Investigator: Tatyana Feldman, MD Collapse << |
NCT00479232 | - | - | Completed | - | - |
NCT00810576 | Lymphoma | Phase 2 | Terminated(Terminated due to s... more >>low accrual.) Collapse << | - | United States, Texas ... more >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01600742 | Brain Metastasis | Phase 2 | Terminated(Sponsor stops to pr... more >>ovide the study drug.) Collapse << | - | Taiwan ... more >> National Taiwan University Hospital Taipei, Taiwan, 100 Collapse << |
NCT00918723 | Chronic Lymphocytic Leukemia ... more >> Stage I Chronic Lymphocytic Leukemia Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage II Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma Collapse << | Phase 1 Phase 2 | Active, not recruiting | October 2019 | United States, Washington ... more >> Swedish Cancer Institute-Breast Center at First Hill Campus Seattle, Washington, United States, 98104 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Collapse << |
NCT00918723 | - | - | Active, not recruiting | - | - |
NCT01039363 | Acute Myeloid Leukemia | Phase 2 | Unknown | - | Korea, Republic of ... more >> Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of, 135-710 Principal Investigator: Dong Hwan Won, M.D.,Ph.D. Collapse << |
NCT01118975 | Breast Cancer ... more >> Neoplasm Metastasis Collapse << | Phase 1 Phase 2 | Terminated(Lost sponsorship fo... more >>r study drug) Collapse << | - | United States, Maryland ... more >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Collapse << |
NCT01118975 | - | - | Terminated(Lost sponsorship fo... more >>r study drug) Collapse << | - | - |
NCT00565227 | Non-Small-Cell Lung Carcinoma ... more >> Prostate Cancer Bladder Cancer Urothelial Carcinoma Collapse << | Phase 1 | Terminated(closed due to toxic... more >>ity) Collapse << | - | United States, Michigan ... more >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Collapse << |
NCT00324740 | - | - | Terminated | - | - |
NCT01608139 | Advanced Cancers | Phase 1 | Withdrawn | - | - |
NCT01421173 | Lymphoma | Phase 1 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00111813 | Multiple Myeloma | Phase 1 | Completed | - | - |
NCT00785798 | Relapsed Lymphomas ... more >> Refractory Lymphomas Collapse << | Phase 1 Phase 2 | Terminated(sponsor requested) | - | United States, Connecticut ... more >> Yale University School of Medicine New Haven, Connecticut, United States, 06520 Collapse << |
NCT00111813 | - | - | Completed | - | - |
NCT01550224 | - | - | Completed | - | - |
NCT01550224 | Acute Myeloid Leukemia With 11... more >>q23-abnormality in Relapse Collapse << | Phase 2 | Completed | - | United States, California ... more >> Stanford University Medical Center Stanford, California, United States, 94305 Collapse << |
NCT01297764 | Multiple Myeloma | Phase 1 Phase 2 | Active, not recruiting | August 2019 | United States, New Jersey ... more >> Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Collapse << |
NCT00324740 | Recurrent Renal Cell Cancer ... more >> Stage III Renal Cell Cancer Stage IV Renal Cell Cancer Collapse << | Phase 1 Phase 2 | Terminated | - | United States, New York ... more >> Montefiore Medical Center - Moses Campus Bronx, New York, United States, 10467-2490 Weill Medical College of Cornell University New York, New York, United States, 10065 Collapse << |
NCT00635791 | Malignant Solid Tumour ... more >> Renal Cell Carcinoma Non Small Cell Lung Carcinoma Collapse << | Phase 1 | Completed | - | United States, Colorado ... more >> University of Colorado Cancer Center Aurora, Colorado, United States, 80045 Collapse << |
NCT01728805 | Cutaneous T-Cell Lymphoma | Phase 3 | Active, not recruiting | December 2018 | - |
NCT00121225 | Ciliary Body and Choroid Melan... more >>oma, Medium/Large Size Extraocular Extension Melanoma Iris Melanoma Uveal Melanoma Recurrent Intraocular Melanoma Recurrent Melanoma Stage IV Melanoma Collapse << | Phase 2 | Completed | - | United States, Pennsylvania ... more >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 Fox Chase Cancer Center Rockledge, Pennsylvania, United States, 19046 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00785798 | - | - | Terminated(sponsor requested) | - | - |
NCT00486720 | Myelodysplastic Syndromes ... more >> Blood Disease Bone Marrow Disease Collapse << | Phase 2 | Terminated | - | - |
NCT00910000 | Ovarian Cancer ... more >> Fallopian Tube Cancer Peritoneal Cancer Collapse << | Phase 1 Phase 2 | Terminated(Terminated due to u... more >>nacceptable toxicity) Collapse << | - | United States, Massachusetts ... more >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT00486720 | - | - | Terminated | - | - |
NCT00121225 | - | - | Completed | - | - |
NCT00910000 | - | - | Terminated(Terminated due to u... more >>nacceptable toxicity) Collapse << | - | - |
NCT01000155 | Sickle Cell Disease ... more >> Sickle Cell Anemia Collapse << | Phase 2 | Terminated(The study terminate... more >>d early due to slow accrual.) Collapse << | - | United States, Massachusetts ... more >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Children's Hospital Boston Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT01000155 | - | - | Terminated(The study terminate... more >>d early due to slow accrual.) Collapse << | - | - |
NCT01587352 | Ocular Melanoma With Extraocul... more >>ar Extension Recurrent Uveal Melanoma Stage IV Uveal Melanoma AJCC v7 Collapse << | Phase 2 | Terminated | - | United States, New York ... more >> Columbia University/Herbert Irving Cancer Center New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Collapse << |
NCT00503971 | Non-small Cell Lung Cancer | Phase 1 Phase 2 | Terminated | - | Spain ... more >> Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08025 Instituto Universitario Dexeus Barcelona, Spain, 08028 Hospital Clinic Barcelona, Spain, 08036 Institut Catalá d'Oncologia, Centre Sanitari i Universitari de Bellvitge (CSUB) Barcelona, Spain, 08907 Institut Catalá d'Oncología, Hospital Germans Trias i Pujol Barcelona, Spain, 08916 Hospital La Paz Madrid, Spain, 28046 Hospital Clínico Universitario de Valencia Valencia, Spain, 46010 Hospital Clínico Lozano Blesa Zaragoza, Spain, 50009 Collapse << |
NCT00773838 | Relapsed or Refractory Multipl... more >>e Myeloma Collapse << | Phase 2 | Completed | - | - |
NCT00776503 | Myelodysplastic Syndromes | Phase 1 Phase 2 | Completed | - | France ... more >> Hôpital de la Durance Avignon, France, 84902 Hopital Avicenne Bobigny, France, 93009 CH René Dubos Cergy-pontoise, France, 95303 Hematology Dpt, Hôpital Sud Francilien Corbeil-essonnes, France, 91100 CHU Grenoble Grenoble, France, 38043 Hôpital Edouard Heriot, dpt Hématologie Clinique Lyon, France, 69437 Hematology Dpt, Institut Paoli Calmettes Marseille, France, 13009 Hematology Dpt, Hopital de l'Hotel Dieu Nantes, France, 44093 Hematology Dpt, Hopital Saint Louis Paris, France, 75475 Hematology Dpt, Hopital Cochin Paris, France, 75679 Centre Henri Bequerel Rouen, France, 76038 Centre René Huguenin Saint Cloud, France, 92210 Hematology Dpt, Hopital Haute Pierre Strasbourg, France, 67098 Hematology Dpt, Hopital Purpan Toulouse, France, 40031 Collapse << |
NCT00773747 | Multiple Myeloma | Phase 3 | Completed | - | - |
NCT00810602 | - | - | Completed | - | - |
NCT01110876 | Brain Cancer ... more >>Glioblastoma Multiforme Collapse << | Phase 1 Phase 2 | Terminated(Unanticipated Toxic... more >>ities) Collapse << | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01790568 | - | - | Completed | - | - |
NCT00561418 | Lymphoma Smal... more >>l Intestine Cancer Collapse << | Phase 1 | Completed | - | United States, Ohio ... more >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 Collapse << |
NCT00810602 | Hematologic Malignancies ... more >> Graft vs Host Disease Collapse << | Phase 1 Phase 2 | Completed | - | United States, Michigan ... more >> University of Michigan Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 Collapse << |
NCT00561418 | - | - | Completed | - | - |
NCT01319383 | HIV-1 Infection | Phase 1 Phase 2 | Completed | - | United States, North Carolina ... more >> The University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27514 Collapse << |
NCT01790568 | Graft vs Host Disease ... more >> Hematologic Neoplasms Non-Neoplastic Hematologic and Lymphocytic Disorder Collapse << | Phase 2 | Completed | - | United States, Michigan ... more >> University of Michigan Cancer Center Ann Arbor, Michigan, United States, 48109 Collapse << |
NCT00667082 | Non-Small Cell Lung Cancer ... more >> Pancreatic Cancer Melanoma Lymphoma Multiple Myeloma Collapse << | Phase 1 | Completed | - | Australia, South Australia ... more >> Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 The Queen Elizabeth Hospital Woodville South, South Australia, Australia, 5011 Australia, Western Australia Sir Charles Gairdner Hospital and University of Western Australia Nedlands, Western Australia, Australia, 6009 Collapse << |
NCT01534260 | - | - | Completed | - | - |
NCT01266057 | Advanced Cancers | Phase 1 | Active, not recruiting | April 2019 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01187446 | - | - | Terminated(Business decision b... more >>y funding source) Collapse << | - | - |
NCT01187446 | Cutaneous Lymphoma ... more >> Cutaneous T-cell Lymphoma Collapse << | Phase 1 Phase 2 | Terminated(Business decision b... more >>y funding source) Collapse << | - | United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06520 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01422499 | Children With Relapsed Solid T... more >>umor, Lymphoma or Leukemia Collapse << | Phase 1 Phase 2 | Completed | - | Germany ... more >> Clinic for Pediatric Oncology, Hematology, Immunology and Clinical Cooperation Unit Pediatric Oncology Heidelberg, BW, Germany, 69198 Childrens's Hospital, Pediatric Oncology and Hematology Augsburg, Germany, 86156 Prof. Hess Childrens's Hospital, Pediatric Oncology and Hematology Bremen, Germany, 28205 University Childrens's Hospital, Pediatric Oncology and Hematology Essen, Germany, 45122 University Children's Hospital, Clinic IV Freiburg, Germany, 79106 Department of Pediatric Oncology and Hematology University Hospital Eppendorf (UKE) Hamburg, Germany, 20246 University Children's Hospital, Pediatric Oncology and Hematology, MHH Hannover, Germany, 30625 University Childrens's Hospital, Pediatric Oncology and Hematology Jena, Germany, 07743 University Children's Hospital, Pediatric Oncology and Hematology Köln, Germany, 50937 Department of Pediatric Oncology and Hematology University Children's Hospital Münster, Germany, 48149 Collapse << |
NCT01319383 | - | - | Completed | - | - |
NCT01534260 | Acute Myeloid Leukemia | Phase 1 Phase 2 | Completed | - | United States, Indiana ... more >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 Collapse << |
NCT00499811 | Adult Grade III Lymphomatoid G... more >>ranulomatosis Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Primary Central Nervous System Hodgkin Lymphoma Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Hodgkin Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Adult T-cell Leukemia/Lymphoma Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Mycosis Fungoides/Sezary Syndrome Stage III Small Lymphocytic Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Stage IV Small Lymphocytic Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Waldenström Macroglobulinemia Collapse << | Phase 1 | Completed | - | United States, California ... more >> City of Hope Medical Center Duarte, California, United States, 91010 University of Southern California Los Angeles, California, United States, 90033 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland National Institutes of Health Bethesda, Maryland, United States, 20892 United States, Michigan Wayne State University-Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467-2490 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, West Virginia West Virginia University Healthcare Morgantown, West Virginia, United States, 26506 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Collapse << |
NCT00772798 | Ovarian Cancer | Phase 2 | Unknown | June 2009 | Denmark ... more >> Department of Oncology R Recruiting Odense, Denmark, DK-5000 C Collapse << |
NCT01059552 | Locally Advanced Non-small Cel... more >>l Lung Cancer Collapse << | Phase 1 | Active, not recruiting | December 1, 2018 | United States, Florida ... more >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 Collapse << |
NCT00667615 | - | - | Completed | - | - |
NCT01502085 | Multiple Myeloma | Phase 1 Phase 2 | Unknown | May 2016 | United States, New Jersey ... more >> John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Collapse << |
NCT00667615 | Hodgkin's Disease ... more >> Lymphoma Collapse << | Phase 1 Phase 2 | Completed | - | United States, New Jersey ... more >> Memorial Sloan Kettering Cancer Center @ BaskingRidge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Weill Cornell Medical Center New York, New York, United States Memorial Sloan Kettering Cancer Center @ Phelps Sleepy Hollow, New York, United States, 10591 Collapse << |
NCT02638090 | Lung Cancer N... more >>on-small Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Recruiting | November 2020 | United States, Florida ... more >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Germaine Gonzalez-Vazquez 813-745-6636 germaine.gonzalezvazquez@moffitt.org Contact: Jhanelle Gray, M.D. 813-745-7282 jhanelle.gray@moffitt.org Principal Investigator: Jhanelle Gray, M.D. Sub-Investigator: Scott Antonia, M.D., Ph.D. Sub-Investigator: Ben Creelan, M.D. Sub-Investigator: Eric Haura, M.D. Sub-Investigator: Tawee Tanvetyanon, M.D. Sub-Investigator: Charles Williams, Jr., M.D. Collapse << |
NCT00697476 | Small Cell Lung Cancer | Phase 1 Phase 2 | Terminated(insufficient enroll... more >>ment) Collapse << | - | Italy ... more >> Istituto Clinico Humanitas Rozzano, Milan, Italy, 20089 Collapse << |
NCT00831493 | - | - | Terminated(Slow Accrual.) | - | - |
NCT00972842 | Peripheral T-Cell Non-Hodgkin'... more >>s Lymphoma Collapse << | Phase 1 Phase 2 | Terminated(slow recruitment) | - | Austria ... more >> Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie Innsbruck, Tirol, Austria, A-6020 Krankenhaus der Elisabethinen Linz Linz, Austria, A-4010 Krankenhaus der Stadt Linz Linz, Austria, A-4020 Universitaetsklinik f. Innere Medizin III Salzburg, Austria, A-5020 Hanusch Krankenhaus Vienna, Austria, A-1140 Collapse << |
NCT02420613 | Diffuse Intrinsic Pontine Glio... more >>ma Collapse << | Phase 1 | Recruiting | October 2020 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse << |
NCT00831493 | Pancreatic Cancer | Phase 1 Phase 2 | Terminated(Slow Accrual.) | - | United States, Texas ... more >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00948688 | - | - | Terminated(Funding was withdra... more >>wn after only 10 participants were enrolled) Collapse << | - | - |
NCT01075113 | Liver Cancer | Phase 1 | Active, not recruiting | January 31, 2023 | United States, Virginia ... more >> Hunter Holmes McGuire VA Medical Center Richmond, Virginia, United States, 23249 Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Collapse << |
NCT01276717 | Lymphoma | Phase 1 | Completed | - | United States, New York ... more >> University of Rochester Rochester, New York, United States, 14642 United States, Virginia Virginia Commonwealth University Massey Cancer Center Richmond, Virginia, United States, 23298 Collapse << |
NCT00948688 | Pancreatic Cancer ... more >> Adenocarcinoma of the Pancreas Collapse << | Phase 1 Phase 2 | Terminated(Funding was withdra... more >>wn after only 10 participants were enrolled) Collapse << | - | United States, Massachusetts ... more >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT00976183 | - | - | Terminated(toxicities) | - | - |
NCT00821951 | - | - | Completed | - | - |
NCT01266031 | - | - | Completed | - | - |
NCT01266031 | Malignant Glioma ... more >> Recurrent Glioblastoma Collapse << | Phase 1 Phase 2 | Completed | - | United States, Texas ... more >> Baylor University Medical Center Dallas, Texas, United States, 75246 Collapse << |
NCT01748240 | Myelodysplastic Syndrome | Phase 2 | Terminated(inefficiency) | - | France ... more >> CHU d'Angers Angers, France, 49033 CH Annecy Annecy, France, 74374 Hôpital Avignon Avignon, France, 84000 Centre hospitalier de la côte Basque Bayonne, France, 64100 Hôpital Avicenne Bobigny, France, 93009 CHU de Haut-Lévèque Bordeaux Pessac, France, 33604 CHU de Grenoble Grenoble, France, 38043 CH Le mans Le mans, France, 72037 CH Lyon Sud Lyon, France, 69495 IPC-Unité d'Hématologie 3 Marseille, France, 13273 CHU Nantes Nantes, France, 44093 Hôpital Archet1 Nice, France, 06202 GHU Caremeau Nimes, France, 30029 Hôpital Saint Louis Paris, France, 75010 Hopital Saint Louis - AP-HP, Hematology Dpt Paris, France, 75475 Hôpital Saint-Louis Paris, France, 75475 Hopital Cochin-Hematology Paris, France, 75679 Centre Hospitalier Joffre Perpignan, France, 66046 Centre Henri Becquerel Rouen, France, 76038 Hopital Purpan-Medecine interne Toulouse, France, 31059 Hôpital PURPAN, Service d'Hématologie Clinique Toulouse, France, 31059 CHU Bretonneau Tours, France, 37044 CH de Valence Valence, France, 26953 CHU Brabois Vandoeuvre, France, 54511 Collapse << |
NCT00976183 | Ovarian Neoplasms | Phase 1 Phase 2 | Terminated(toxicities) | - | United States, California ... more >> Gynecologic Oncology Associates Newport Beach, California, United States, 92663 Collapse << |
NCT01748240 | - | - | Terminated(inefficiency) | - | - |
NCT01339871 | Advanced Cancer | Phase 1 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT02589145 | Lymphoma | Phase 1 Phase 2 | Active, not recruiting | June 2021 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00821951 | Non-Small Cell Lung Cancer (NS... more >>CLC) Collapse << | Phase 1 | Completed | - | United States, Connecticut ... more >> Yale University School of Medicine New Haven, Connecticut, United States, 06520 Collapse << |
NCT03198559 | HIV Infections | Phase 1 Phase 2 | Suspended(Review of current ad... more >>verse events reported by study participants) Collapse << | July 2027 | Australia, Victoria ... more >> Department of Infectious Diseases, Alfred Hospital Melbourne, Victoria, Australia, 3004 Collapse << |
NCT00838929 | Brain Metastases | Phase 1 | Completed | - | United States, Pennsylvania ... more >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 United States, Texas The University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Collapse << |
NCT00875745 | Leukemia, Myeloid, Acute ... more >> Leukemia, Promyelocytic, Acute Myelodysplastic Syndromes Collapse << | Phase 1 | Completed | - | United States, Indiana ... more >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 Collapse << |
NCT00801151 | Malignant Solid Tumour | Phase 1 | Terminated | - | France ... more >> Centre René GAUDUCHEAU Nantes Saint Herblain, France, 44805 Institut Curie Paris, France, 75005 Institut Claudius REGAUD Toulouse, France, 31052 Collapse << |
NCT00838929 | - | - | Completed | - | - |
NCT01194427 | Stage I Breast Cancer ... more >> Stage II Breast Cancer Stage III Breast Cancer Invasive Breast Cancer Collapse << | Phase 2 | Terminated(Difficulty meeting ... more >>patient accrual goals) Collapse << | - | United States, Maryland ... more >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21287 Collapse << |
NCT01194427 | - | - | Terminated(Difficulty meeting ... more >>patient accrual goals) Collapse << | - | - |
NCT01720875 | Multiple Myeloma | Phase 2 | Unknown | August 2017 | United Kingdom ... more >> Nottingham University Hospital Nottingham, Nottinghamshire, United Kingdom, NG5 1PB University Hospital Southampton Southampton, United Kingdom, SO16 6YD Collapse << |
NCT00735826 | Aerodigestive Tract Cancer ... more >> Lung Cancer Esophageal Cancer Head and Neck Cancer Collapse << | Not Applicable | Completed | - | United States, New Hampshire ... more >> Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 Collapse << |
NCT00735826 | - | - | Completed | - | - |
NCT01023737 | Malignant Solid Tumour | Phase 1 | Active, not recruiting | September 2020 | United States, Texas ... more >> Cancer Therapy & Research Center University of Texas Health Science Center San Antonio San Antonio, Texas, United States, 78229 Collapse << |
NCT00918489 | Soft Tissue Sarcoma | Phase 2 | Completed | - | Germany ... more >> Department of Hematology, Oncology, Rheumatology and Immunology, University Hospital Tübingen Tübingen, Baden-Württemberg, Germany, D-72076 Department of Hematology, Hemostaseology, Oncology and Stemm Cell Transplantation, Medical School Hannover Hannover, Niedersachen, Germany, D-30625 Department of Oncology, Hematology and Palliative Medicine, Marien Hospital Düsseldorf Düsseldorf, Nordrhein-Westfalen, Germany, D-40479 Comprehensive Cancer Center North, University Hospital Kiel Kiel, Germany, 24105 Sarcoma Center Mannheim, University Hospital Mannheim Mannheim, Germany, 68167 Center for Soft Tissue Sarcoma, University Hospital Tübingen Tübingen, Germany, 72074 Comprehensive Cancer Center Ulm (CCCU) Ulm, Germany, 89081 Collapse << |
NCT00702962 | - | - | Terminated(Poor accrual) | - | - |
NCT02042989 | Advanced Cancers | Phase 1 | Active, not recruiting | June 2022 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT02124083 | Neimann-Pick Disease | Phase 1 Phase 2 | Completed | - | United States, Maryland ... more >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Collapse << |
NCT00702962 | Small Cell Lung Cancer | Phase 1 Phase 2 | Terminated(Poor accrual) | - | United States, Pennsylvania ... more >> Penn State College of Medicine, Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania, United States, 17033 Collapse << |
NCT02151721 | Non-Small-Cell Lung Carcinoma | Phase 1 | Active, not recruiting | February 20, 2018 | Japan ... more >> Nagoya University Graduate School of Medicine Nagoya, Aichi, Japan, 466-8560 Institute of Biomedical Research and Innovation Hospital Kobe, Hyogo-ken, Japan, 650-0047 Kanazawa University Hospital Kanazawa, Ishikawa, Japan, 920-0934 Tohoku University Hospital Sendai, Miyagi, Japan, 980-8574 Shizuoka Cancer Center Sunto-gun, Shizuoka, Japan, 411-8777 Collapse << |
NCT02619253 | Renal Cell Carcinoma ... more >> Urinary Bladder Neoplasms Collapse << | Phase 1 | Recruiting | May 31, 2020 | United States, California ... more >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Charis Barg, RN 323-865-0845 charis.barg@med.usc.edu Principal Investigator: David Quinn, MD United States, Indiana Indiana University Hospital Recruiting Indianapolis, Indiana, United States, 46202 Contact: Marietta Moore, RN 317-274-7477 marlmoor@iu.edu Principal Investigator: Roberto Pili, MD Indiana University Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Marietta Moore, RN 317-274-7477 marlmoor@iu.edu Principal Investigator: Roberto Pili, MD IU Health Central Indiana Cancer Centers (CICC) Recruiting Indianapolis, Indiana, United States, 46219 Contact: Deb Racster, RN 317-727-6549 dracster@iuhealth.org Principal Investigator: Andrew Greenspan, MD United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21205 Contact: Connie Collins 410-955-1017 ccolli23@jhmi.edu Principal Investigator: Noah Hahn, MD Collapse << |
NCT02124083 | - | - | Completed | - | - |
NCT01365065 | HIV Positive | Phase 2 | Active, not recruiting | January 2018 | Australia, Victoria ... more >> The Alfred Hospital - Infectious Diseases Unit Melbourne, Victoria, Australia, 3004 Collapse << |
NCT02836548 | Melanoma Skin... more >> Neoplasms Collapse << | Phase 1 Phase 2 | Recruiting | October 2019 | Netherlands ... more >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066 CX Contact: N Steeghs, MD, PhD Collapse << |
NCT01294670 | Solid Tumors ... more >>Relapsed/Refractory Sarcomas Collapse << | Phase 1 Phase 2 | Active, not recruiting | February 2019 | United States, Arizona ... more >> Phoenix Children'S Hospital Phoenix, Arizona, United States, 85016 United States, Colorado Children's Hospital Colorado Aurora, Colorado, United States, 80045 United States, Florida Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando Orlando, Florida, United States, 32806 All Children's Hospital Saint Petersburg, Florida, United States, 33701 United States, Maryland John Hopkins Medical Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Children's Mercy Hospital & Clinics Kansas City, Missouri, United States, 64108 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania Pennsylvania State University College of Medicine Hershey, Pennsylvania, United States, 17110 United States, Texas Md Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Alberta Alberta Children'S Hospital Calgary, Alberta, Canada, T2N 1N4 Collapse << |
NCT02707900 | HIV-1 Infection | Phase 1 | Terminated(Manufacturing of th... more >>e AGS-004 HIV vaccine by Argos could no longer be provided.) Collapse << | - | United States, North Carolina ... more >> University of North Carolina Hospitals Chapel Hill, North Carolina, United States, 27599-7030 Collapse << |
NCT03742245 | Breast Cancer Metastatic ... more >> Breast Cancer Collapse << | Phase 1 | Not yet recruiting | September 1, 2022 | United States, Texas ... more >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01500538 | Follicular Lymphoma ... more >> Marginal Zone Lymphoma Mantle Cell Lymphoma Collapse << | Phase 2 | Terminated(Poor recruitment ra... more >>te) Collapse << | - | Australia, Victoria ... more >> Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3002 Collapse << |
NCT03056495 | Alzheimer Disease | Phase 1 | Recruiting | October 2019 | Germany ... more >> German Center for Neurodegenerative Diseases Recruiting Bonn, Germany, 53127 Contact: Anja Schneider, Prof. Dr. med. 0049-228-287-1137 anja.schneider@dzne.de University Medical Center Göttingen, Department of Psychiatry and Psychotherapy Recruiting Göttingen, Germany, 37075 Contact: Jens Wiltfang, Prof. Dr. med. 0049-551-3966601 jens.wiltfang@med.uni-goettingen.de Collapse << |
NCT03509207 | Leiomyosarcoma ... more >> Endometrial Stromal Tumors Carcinosarcomas Uterine Collapse << | Phase 2 | Recruiting | December 31, 2019 | Austria ... more >> Medical University of Graz, Clinic of Obstetrics and Gynecology Recruiting Graz, Austria, 8036 Contact: Edgar Petru, Prof. MD +43 316 385 ext 13810 edgar.petru@medunigraz.at Principal Investigator: Edgar Petru, MD Collapse << |
NCT03022565 | Uveal Melanoma | Early Phase 1 | Recruiting | December 2025 | United States, Florida ... more >> University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Andrea Pena 305-243-7592 a.palomino@med.miami.edu Contact: Lynn Feun, MD 305-243-6606 lfeun@med.miami.edu Principal Investigator: Lynn Feun, MD Collapse << |
NCT01578343 | Mantle Cell Lymphoma | Phase 2 | Terminated(we collected data o... more >>f a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.) Collapse << | - | Korea, Republic of ... more >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Collapse << |
NCT01045538 | Gastric Cancer ... more >> Histone Deacetylase Inhibitor Collapse << | Phase 1 Phase 2 | Completed | - | Korea, Republic of ... more >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Collapse << |
NCT02645149 | Melanoma | Phase 4 | Not yet recruiting | August 2021 | Australia, New South Wales ... more >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez 612 9911 7200 maria.gonzalez@melanoma.org.au Principal Investigator: John Thompson Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez +612 9911 7200 maria.gonzalez@melanoma.org.au Contact: Alex Menzies +612 9911 7200 info@melanoma.org.au Sub-Investigator: Georgina Long Principal Investigator: Alex Menzies Collapse << |
NCT01142375 | - | - | Unknown | - | - |
NCT00007345 | Cutaneous T Cell Lymphoma ... more >> Peripheral T Cell Lymphoma Collapse << | Phase 2 | Completed | - | United States, Arizona ... more >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259 United States, Arkansas University of Arkansas Little Rock, Arkansas, United States, 72205 United States, California City of Hope National Cancer Center Duarte, California, United States, 91010 Mercy General Hospital Sacramento, California, United States, 95819 United States, District of Columbia Georgetown University Washington, District of Columbia, United States, 20007-2197 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 United States, New York North Shore University Hospital Manhasset, New York, United States, 11030 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15261 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 Australia Royal Adelaide Hospital Adelaide, Australia Peter MacCallum Cancer Centre Melbourne, Australia Sir Charles Gairdner Hospital Perth, Australia Collapse << |
NCT02788201 | Urothelial Carcinoma ... more >> Bladder Cancer Urinary Bladder Neoplasms Collapse << | Phase 2 | Recruiting | July 1, 2020 | United States, Maryland ... more >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Collapse << |
NCT00007345 | - | - | Completed | - | - |
NCT01655004 | Breast Carcinoma | Not Applicable | Unknown | August 2018 | Singapore ... more >> National University Hospital Recruiting Singapore, Singapore, 119074 Contact: Andrea LA Wong, MBBS (65) 6772 5934 andrea_la_wong@nuhs.edu.sg Sub-Investigator: Soo Chin Lee, MBBS Sub-Investigator: Siew Eng Lim, MBBS Sub-Investigator: Sing Huang Tan, MBBS Collapse << |
NCT03117751 | Acute Lymphoblastic Leukemia ... more >> Acute Lymphoblastic Lymphoma Collapse << | Phase 2 Phase 3 | Recruiting | March 31, 2028 | United States, Tennessee ... more >> St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Hiroto Inaba, MD, PhD 866-278-5833 referralinfo@stjude.org Principal Investigator: Hiroto Inaba, MD, PhD Collapse << |
NCT01663571 | - | - | Terminated(Study is permanentl... more >>y closed to enrollment .Collection of private identifiable information is complete Analysis of private identifiable information is complete) Collapse << | - | United States, New York ... more >> NYU Langone Medical Center New York, New York, United States, 10016 Collapse << |
NCT02559778 | Neuroblastoma | Phase 2 | Recruiting | September 2026 | - |
NCT00858234 | Multiple Myeloma | Phase 1 | Completed | - | - |
NCT02553460 | Acute Lymphoblastic Leukemia | Phase 1 Phase 2 | Recruiting | October 2031 | United States, California ... more >> Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Paul Gaynon, MD 323-361-4110 pgaynon@chla.usc.edu Principal Investigator: Paul Gaynon, MD Children's Hospital of Orange County Recruiting Orange, California, United States, 92868 Contact: Ivan Kirov, MD 714-997-3000 ikirov@choc.org Principal Investigator: Ivan Kirov, MD Lucile Packard Children's Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Norman J. Lacayo, MD 650-497-8953 lacayon@stanford.edu Principal Investigator: Norman J. Lacayo, MD Rady Children's Hospital and Health Center Recruiting San Diego, California, United States, 92123 Contact: Deborah Schiff, MD 858-966-5983 dschiff@chsd.org Principal Investigator: Deborah Schiff, MD United States, Minnesota Children's Hospital and Clinics of Minnesota Recruiting Minneapolis, Minnesota, United States, 55102 Contact: Michael Richards, MD 612-813-5193 Michael.richards@childrensmn.org Principal Investigator: Michael Richards, MD United States, North Carolina St. Jude Affiliate-Charlotte Recruiting Charlotte, North Carolina, United States, 28204 Contact: Christine Bolen, MD 704-384-1900 cybolen@novanthealth.org Principal Investigator: Christine Bolen, MD United States, Ohio Cincinnati Children's Hospital Recruiting Cincinnati, Ohio, United States, 45229 Contact: Erin Breese, MD, PhD 513-636-2799 erin.breese@cchmc.org Principal Investigator: Erin Breese, MD, PhD Rainbow Babies & Children's Hospital Recruiting Cleveland, Ohio, United States, 44106 Contact: Yousif Matloub, MD 216-844-5437 yousif.matloub@uhhospitals.org Principal Investigator: Yousif Matloub, MD United States, Oregon Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239 Contact: Bill Chang, MD 503-494-1080 changb@ohsu.edu Principal Investigator: Bill Chang, MD United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Tanja A. Gruber, MD, PhD 866-278-5833 tanja.gruber@stjude.org Contact: Referral Office 866-278-5833 referralinfo@stjude.org Principal Investigator: Tanja A. Gruber, MD, PhD United States, Virginia Children's Hospital of the King's Daughters (CHKD) Recruiting Norfolk, Virginia, United States, 23507 Contact: Eric Lowe, MD 757-668-7243 eric.lowe@chkd.org Principal Investigator: Eric Lowe, MD Canada, Alberta Alberta Children's Hospital Recruiting Calgary, Alberta, Canada, T3A 6A8 Contact: Victor A. Lewis, MD 403-220-6898 victor.lewis@ahs.ca Principal Investigator: Victor A. Lewis, MD Stollery Children's Hospital Recruiting Edmonton, Alberta, Canada, T6G 2B7 Contact: Sunil Desai, M.B.Ch.B., FRCP(c) 780-248-5415 sunil.desai@ahs.ca Principal Investigator: Sunil Desai, M.B.Ch.B., FRCP(c) Canada, British Columbia Children's & Women's Health Centre of British Columbia Recruiting Vancouver, British Columbia, Canada, V6H 3V4 Contact: Kirk R. Schultz, MD 604-875-2345 ext 6477 kschultz@mail.ubc.ca Principal Investigator: Kirk R. Schultz, MD Canada, Ontario McMaster Children's Hospital at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L85 4J9 Contact: Uma Athale, MD 905-521-2100 ext 73376 athaleu@mcmaster.ca Principal Investigator: Uma Athale, MD Canada, Quebec The Montreal Children's Hospital (MUHC-McGill) Recruiting Montreal, Quebec, Canada, H4A 3J1 Contact: Catherine Vezina, MD 514-412-4445 catherine.vezina@muhc.mcgill.ca Principal Investigator: Catherine Vezina, MD Centre Hospitalier Universitaire Sainte-Justine Recruiting Montreal, Quebec, Canada, HcT 1C5 Contact: Henrique Bittencourt, MD 514-345-4931 henrique.bittencourt.hsj@ssss.gouv.qc.ca Contact: Yvan Samson yvan.samson@umontreal.ca Principal Investigator: Henrique Bittencourt, MD Centre Hospitalier Universitaire de Quebec Recruiting Québec, Quebec, Canada, G1V 4G2 Contact: Bruno Michon, MD 418-525-4444 bruno.michon@mail.chuq.qc.ca Principal Investigator: Bruno Michon, MD Collapse << |
NCT03259503 | Malignant Neoplasms Stated as ... more >>Primary Lymphoid Haematopoietic Lymphoma Collapse << | Phase 1 Phase 2 | Not yet recruiting | May 2019 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact ynieto@mdanderson.org Collapse << |
NCT01249443 | HIV Infection ... more >> Recurrent Anal Cancer Recurrent Breast Cancer Recurrent Esophageal Cancer Recurrent Gastric Cancer Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Anal Cancer Stage IV Breast Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Unspecified Adult Solid Tumor, Protocol Specific Collapse << | Phase 1 | Terminated(Inadequate accrual ... more >>rate) Collapse << | - | United States, California ... more >> UC San Diego Moores Cancer Center La Jolla, California, United States, 92093 UCLA Center for Clinical AIDS Research and Education Los Angeles, California, United States, 90035 United States, District of Columbia Lombardi Comprehensive Cancer Center at Georgetown University Washington, District of Columbia, United States, 20057 United States, Florida University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States, 33136 United States, Illinois John H. Stroger Jr. Hospital of Cook County Chicago, Illinois, United States, 60612 United States, Massachusetts Boston Medical Center Boston, Massachusetts, United States, 02118 United States, Missouri Siteman Cancer Center at Washington University Saint Louis, Missouri, United States, 63110 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467-2490 United States, Pennsylvania Pennsylvania Oncology Hematology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Washington Benaroya Research Institute at Virginia Mason Seattle, Washington, United States, 98101-2795 Collapse << |
NCT02114502 | Myeloma | Phase 2 | Withdrawn | - | - |
NCT00424775 | - | - | Terminated | - | - |
NCT02336074 | HIV | Phase 2 | Active, not recruiting | November 2022 | United Kingdom ... more >> Brighton and Sussex University Hospitals NHS Trust Brighton, United Kingdom Central and North West London NHS Foundation Trust London, United Kingdom Chelsea and Westminster NHS Foundation Trust London, United Kingdom Guy's and St Thomas' NHS Foundation Trust London, United Kingdom Imperial College Healthcare NHS Trust London, United Kingdom Royal Free Hospital NHS Foundation Trust London, United Kingdom Collapse << |
NCT03382834 | HIV Infections | Early Phase 1 | Active, not recruiting | June 30, 2023 | United States, Alabama ... more >> Alabama CRS Birmingham, Alabama, United States, 35294 United States, California UCLA CARE Center CRS Los Angeles, California, United States, 90035 Ucsf Hiv/Aids Crs San Francisco, California, United States, 94110 Harbor-UCLA CRS Torrance, California, United States, 90502 United States, Colorado University of Colorado Hospital CRS Aurora, Colorado, United States, 80045 United States, District of Columbia Whitman-Walker Health CRS Washington, District of Columbia, United States, 20005 United States, Georgia The Ponce de Leon Center CRS Atlanta, Georgia, United States, 30308-2012 United States, Illinois Northwestern University CRS Chicago, Illinois, United States, 60611 United States, Massachusetts Massachusetts General Hospital CRS (MGH CRS) Boston, Massachusetts, United States, 02114 United States, New Jersey New Jersey Medical School Clinical Research Center CRS Newark, New Jersey, United States, 07103 United States, North Carolina Chapel Hill CRS Chapel Hill, North Carolina, United States, 27599 Greensboro CRS Greensboro, North Carolina, United States, 27401 United States, Ohio Cincinnati Clinical Research Site Cincinnati, Ohio, United States, 45219 United States, Pennsylvania Penn Therapeutics, CRS Philadelphia, Pennsylvania, United States, 19104 Puerto Rico Puerto Rico AIDS Clinical Trials Unit CRS San Juan, Puerto Rico, 00935 Collapse << |
NCT02412475 | Leukemia, Acute Myeloid | Phase 1 | Active, not recruiting | February 2019 | United States, Minnesota ... more >> Children's Hospitals and Clinics of Minnesota Minneapolis, Minnesota, United States, 55404 United States, Wisconsin Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States, 53226 Collapse << |
NCT00424775 | Neoplasms | Phase 1 | Terminated | - | - |
NCT00750178 | Cancer, Advanced | Phase 1 | Completed | - | - |
NCT00097929 | B-cell Lymphoma | Phase 2 | Completed | - | - |
NCT00126451 | Breast Cancer ... more >> Colorectal Cancer Non-small-cell Lung Carcinoma Collapse << | Phase 2 | Terminated | - | - |
NCT00091559 | Cutaneous T-cell Lymphoma ... more >> Sezary Syndrome Mycosis Fungoides Collapse << | Phase 2 | Completed | - | - |
NCT02475915 | Acute HIV Infection | Phase 1 Phase 2 | Completed | - | Thailand ... more >> SEARCH, the Thai Red Cross AIDS Research Centre Bangkok, Thailand, 10330 Collapse << |
NCT03713320 | Cutaneous T-Cell Lymphoma/Myco... more >>sis Fungoides Collapse << | Phase 2 | Recruiting | September 2021 | United States, California ... more >> City of Hope Recruiting Duarte, California, United States, 91010 Contact: Rosemarie Abary 626-218-8087 rabary@coh.org Principal Investigator: Christiane Querfeld, MD Chao Family Comprehensive Cancer Center at University of California, Irvine Recruiting Orange, California, United States, 92868 Contact: Blake Johnson 714-456-3476 Blakej@uci.edu Principal Investigator: Lauren Pinter-Brown, MD United States, Connecticut Smilow Cancer Hospital at Yale-New Haven Not yet recruiting New Haven, Connecticut, United States, 06510 Principal Investigator: Francine Foss, MD United States, Florida Moffitt Cancer Center Not yet recruiting Tampa, Florida, United States, 33612 Principal Investigator: Lubomir Sokol, MD, PhD United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63108 Contact: Mary Tabacchi, CCRC 314-362-8171 mtabacch@wustl.edu Principal Investigator: Amy Musiek, MD United States, New York Rochester Skin Lymphoma Medical Group Not yet recruiting Fairport, New York, United States, 14450 Principal Investigator: Brian Poligone, MD, PhD United States, Ohio The Ohio State University Comprehensive Cancer Center Not yet recruiting Columbus, Ohio, United States, 43210 Principal Investigator: Basem William, MD Canada, Alberta Cross Cancer Institute Not yet recruiting Edmonton, Alberta, Canada, T6G 1Z2 Principal Investigator: Minakshi Taparia, MD Canada, Ontario Princess Margaret Cancer Centre Not yet recruiting Toronto, Ontario, Canada, M5G 2C1 Principal Investigator: Vishal Kukreti, MD Canada, Quebec Jewish General Hospital Not yet recruiting Montréal, Quebec, Canada, H3T 1E2 Principal Investigator: Kevin Pehr, MD Collapse << |
NCT00127101 | Lymphoma | Phase 1 | Terminated(The study was stopp... more >>ed due to low enrollment.) Collapse << | - | - |
NCT00127101 | - | - | Terminated(The study was stopp... more >>ed due to low enrollment.) Collapse << | - | - |
NCT02395627 | Breast Neoplasms | Phase 2 | Recruiting | August 1, 2019 | United States, California ... more >> University of California, San Francisco Medical Center Recruiting San Francisco, California, United States, 94115 Contact: Amy DeLuca 877-827-3222 cancertrials@ucsf.edu Principal Investigator: Pamela Munster, MD Collapse << |
NCT00217412 | Childhood Acute Promyelocytic ... more >>Leukemia (M3) Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Burkitt Lymphoma Childhood Chronic Myelogenous Leukemia Childhood Diffuse Large Cell Lymphoma Childhood Immunoblastic Large Cell Lymphoma Juvenile Myelomonocytic Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Grade III Lymphomatoid Granulomatosis Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Medulloblastoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent/Refractory Childhood Hodgkin Lymphoma Relapsing Chronic Myelogenous Leukemia Unspecified Childhood Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Pennsylvania ... more >> Children's Oncology Group Philadelphia, Pennsylvania, United States, 19104 Collapse << |
NCT00816283 | Leukemia | Phase 1 | Completed | - | United States, California ... more >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010-3000 City of Hope Medical Group Pasadena, California, United States, 91105 Collapse << |
NCT02409134 | - | - | Completed | - | United States, Michigan ... more >> University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Collapse << |
NCT00875056 | Lymphoma | Phase 2 | Active, not recruiting | January 31, 2019 | - |
NCT00005634 | Leukemia Lymp... more >>homa Multiple Myeloma and Plasma Cell Neoplasm Prostate Cancer Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse << |
NCT00310024 | Refractory Multiple Myeloma ... more >> Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Collapse << |
NCT01983969 | Advanced Cancers ... more >> Lymphoma Collapse << | Phase 1 Phase 2 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT02035137 | Neuroblastoma | Phase 2 | Recruiting | December 2019 | United States, California ... more >> Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027-0700 Contact: Araz Marachelian, MD 323-361-5687 amarachelian@chla.usc.edu Lucile Salter Packer Children's Hospital Recruiting Palo Alto, California, United States, 94304 Contact: Sheri Spunt, MD UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 Contact: Katherine Matthay, MD 415-476-3831 matthayK@peds.ucsf.edu United States, Colorado Children Hospital of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Margaret Macy, MD 720-777-8856 Margaret.macy@childrenscolorado.org United States, Georgia AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Recruiting Atlanta, Georgia, United States, 30322 Contact: Kelly Goldsmith, MD 404-785-0853 kgoldsm@emory.edu United States, Illinois University of Chicago, Comer Children's Hospital Recruiting Chicago, Illinois, United States, 60637 Contact: Ami Desai, MD 773-843-3943 adesai12@peds.bsd.uchicago.edu United States, Massachusetts Children's Hospital Boston Recruiting Boston, Massachusetts, United States, 02115 Contact: Suzanne Shusterman, MD 617-632-4901 United States, Michigan C.S Mott Children's Hospital Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Gregory Yanik, MD 734-936-8785 gyanik@umich.edu United States, North Carolina University of North Carolina Not yet recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Patrick Thompson, MD patom@email.unc.edu United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229-3039 Contact: Brian Weiss, MD 513-636-9863 brian.weiss@chmcc.org United States, Pennsylvania Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104-4318 Contact: Yael Mosse, MD 215-590-0965 mosse@chop.edu United States, Texas Cook Children's Healthcare System Recruiting Fort Worth, Texas, United States, 76104 Contact: Meaghan Granger, MD 682-885-4007 United States, Washington Seattle Children's Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Navin Pinto, MD 206-987-5783 navin.pinto@seattlechildrens.org Canada, Ontario Hospital for Sick Children Recruiting Toronto, Ontario, Canada, M5G1X8 Contact: Meredith Irwin, MD Collapse << |
NCT00109109 | Multiple Myeloma | Phase 1 | Terminated | - | - |
NCT00423449 | Non-Small Cell Lung Cancer | Phase 1 | Completed | - | - |
NCT00423449 | - | - | Completed | - | - |
NCT00574587 | Breast Cancer | Phase 1 Phase 2 | Unknown | January 2016 | United States, New York ... more >> Montefiore Medical Center Bronx, New York, United States, 10461 Collapse << |
NCT00589472 | Prostate Adenocarcinoma ... more >> Stage I Prostate Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer Collapse << | Phase 2 | Completed | - | United States, California ... more >> UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 UCSF Medical Center-Parnassus San Francisco, California, United States, 94143 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New Jersey UMDNJ - New Jersey Medical School Newark, New Jersey, United States, 07103 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98195 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Collapse << |
NCT02943642 | Mycosis Fungoides | Phase 2 | Not yet recruiting | May 2020 | - |
NCT00589472 | - | - | Completed | - | - |
NCT00473889 | Stage IIIB or IV Non-Small Cel... more >>l Lung Cancer Collapse << | Phase 2 Phase 3 | Terminated(The study was termi... more >>nated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.) Collapse << | - | - |
NCT01554852 | Multiple Myeloma | Phase 3 | Active, not recruiting | December 2022 | United Kingdom ... more >> 112 sites UK wide United Kingdom, United Kingdom Collapse << |
NCT00455351 | Pelvic Cancer ... more >> Radiotherapy Collapse << | Phase 1 | Completed | - | Norway ... more >> The Norwegian Radium Hospital Oslo, Norway, NO-0310 Collapse << |
NCT00045006 | Cancer | Phase 1 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse << |
NCT00537121 | Esophageal Cancer ... more >> Gastric Cancer Liver Cancer Collapse << | Phase 1 | Completed | - | United States, New York ... more >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 Collapse << |
NCT01076530 | Childhood Atypical Teratoid/Rh... more >>abdoid Tumor Childhood Central Nervous System Choriocarcinoma Childhood Central Nervous System Embryonal Tumor Childhood Central Nervous System Germinoma Childhood Central Nervous System Mixed Germ Cell Tumor Childhood Central Nervous System Teratoma Childhood Central Nervous System Yolk Sac Tumor Childhood Choroid Plexus Tumor Childhood Craniopharyngioma Childhood Ependymoblastoma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood High-grade Cerebellar Astrocytoma Childhood High-grade Cerebral Astrocytoma Childhood Infratentorial Ependymoma Childhood Low-grade Cerebellar Astrocytoma Childhood Low-grade Cerebral Astrocytoma Childhood Medulloepithelioma Childhood Mixed Glioma Childhood Oligodendroglioma Childhood Supratentorial Ependymoma Extra-adrenal Paraganglioma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Central Nervous System Embryonal Tumor Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Recurrent Childhood Spinal Cord Neoplasm Recurrent Childhood Subependymal Giant Cell Astrocytoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway and Hypothalamic Glioma Collapse << | Phase 1 | Completed | - | United States, Illinois ... more >> Childrens Memorial Hospital Chicago, Illinois, United States, 60614 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, Minnesota University of Minnesota Medical Center-Fairview Minneapolis, Minnesota, United States, 55455 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Canada, Quebec Hospital Sainte-Justine Montreal, Quebec, Canada, H3T 1C5 Collapse << |
NCT01386398 | Lymphoma | Phase 3 | Withdrawn(Company withdrew int... more >>erest) Collapse << | - | - |
NCT00324870 | Clear Cell Renal Cell Carcinom... more >>a Recurrent Renal Cell Cancer Stage III Renal Cell Cancer Stage IV Renal Cell Cancer Collapse << | Phase 1 Phase 2 | Completed | - | United States, Maryland ... more >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 Peninsula Oncology and Hematology PA Salisbury, Maryland, United States, 21801 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Collapse << |
NCT00127127 | Tumors | Phase 1 | Completed | - | - |
NCT02083250 | Acute Lymphoblastic Leukemia i... more >>n Remission Acute Myeloid Leukemia in Remission Allogeneic Hematopoietic Stem Cell Transplantation Recipient Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Collapse << | Phase 1 | Active, not recruiting | March 30, 2021 | United States, Texas ... more >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00324870 | - | - | Completed | - | - |
NCT01802333 | Acute Myeloid Leukemia ... more >> Untreated Adult Acute Myeloid Leukemia Collapse << | Phase 3 | Completed | - | - |
NCT03263936 | Acute Myelogenous Leukemia | Phase 1 | Recruiting | July 2020 | - |
NCT00555399 | Glioblastoma Multiforme ... more >> Anaplastic Glioma Collapse << | Phase 1 Phase 2 | Active, not recruiting | November 2019 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01483690 | Acute Lymphoblastic Leukemia ... more >> Precursor B-Cell Lymphoblastic Leukemia Precursor T-Cell Lymphoblastic Leukemia Collapse << | Phase 1 Phase 2 | Terminated(Toxicity) | - | - |
NCT00473889 | - | - | Terminated(The study was termi... more >>nated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.) Collapse << | - | - |
NCT00601718 | - | - | Completed | - | - |
NCT00616967 | Breast Cancer | Phase 2 | Completed | - | United States, Alabama ... more >> University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States, 35249 United States, Indiana Indiana University Purdue University of Indianapolis Indianapolis, Indiana, United States, 46202 United States, Maryland Anne Arundel Health System Annapolis, Maryland, United States, 21401 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 Collapse << |
NCT00764517 | - | - | Completed | - | - |
NCT00616967 | - | - | Completed | - | - |
NCT00258349 | Breast Cancer ... more >> Male Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Collapse << | Phase 1 Phase 2 | Completed | - | United States, Alabama ... more >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Iowa Mercy Capitol Des Moines, Iowa, United States, 50307 Iowa Methodist Medical Center Des Moines, Iowa, United States, 50309 Iowa Oncology Research Association CCOP Des Moines, Iowa, United States, 50309 Medical Oncology and Hematology Associates-Des Moines Des Moines, Iowa, United States, 50309 Medical Oncology and Hematology Associates Des Moines, Iowa, United States, 50314 Mercy Medical Center - Des Moines Des Moines, Iowa, United States, 50314 Iowa Lutheran Hospital Des Moines, Iowa, United States, 50316 Siouxland Hematology Oncology Associates Sioux City, Iowa, United States, 51101 Mercy Medical Center-Sioux City Sioux City, Iowa, United States, 51104 Saint Luke's Regional Medical Center Sioux City, Iowa, United States, 51104 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 United States, Massachusetts Eastern Cooperative Oncology Group Boston, Massachusetts, United States, 02215 United States, Minnesota Hutchinson Area Health Care Hutchinson, Minnesota, United States, 55350 Meeker County Memorial Hospital Litchfield, Minnesota, United States, 55355 Saint John's Hospital - Healtheast Maplewood, Minnesota, United States, 55109 Virginia Piper Cancer Institute Minneapolis, Minnesota, United States, 55407 Hennepin County Medical Center Minneapolis, Minnesota, United States, 55415 Regions Hospital Saint Paul, Minnesota, United States, 55101 Saint Joseph's Hospital - Healtheast Saint Paul, Minnesota, United States, 55102 Saint Francis Regional Medical Center Shakopee, Minnesota, United States, 55379 Woodwinds Health Campus Woodbury, Minnesota, United States, 55125 United States, New York Albert Einstein College of Medicine Bronx, New York, United States, 10461 Montefiore Medical Center Bronx, New York, United States, 10467-2490 Saint Vincent's Hospital and Medical Center of New York New York, New York, United States, 10011 Collapse << |
NCT00764517 | Recurrent B-Cell Non-Hodgkin L... more >>ymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Indolent Adult Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Collapse << | Phase 2 | Completed | - | United States, Oregon ... more >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 Collapse << |
NCT01801670 | - | - | Withdrawn(Enrollment was too s... more >>low, so no participants were ever enrolled.) Collapse << | January 2015 | United States, Massachusetts ... more >> Boston University Boston, Massachusetts, United States, 02118 Collapse << |
NCT00601718 | Adult Nasal Type Extranodal NK... more >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Contiguous Stage II Mantle Cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Mantle Cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Splenic Marginal Zone Lymphoma Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage I Mantle Cell Lymphoma Stage I Mycosis Fungoides/Sezary Syndrome Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Stage II Mycosis Fungoides/Sezary Syndrome Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Mantle Cell Lymphoma Stage III Mycosis Fungoides/Sezary Syndrome Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Waldenström Macroglobulinemia Collapse << | Phase 1 Phase 2 | Completed | - | United States, Washington ... more >> Puget Sound Oncology Consortium Seattle, Washington, United States, 98109 Collapse << |
NCT00258349 | - | - | Completed | - | - |
NCT00867178 | Medulloblastoma ... more >> Pineoblastoma Supratentorial Embryonal Tumor, Not Otherwise Specified Untreated Childhood Medulloblastoma Untreated Childhood Pineoblastoma Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor Collapse << | Not Applicable | Active, not recruiting | - | United States, California ... more >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Illinois Lurie Children's Hospital-Chicago Chicago, Illinois, United States, 60611 United States, Maryland National Cancer Institute Pediatric Oncology Branch Bethesda, Maryland, United States, 20892 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee Pediatric Brain Tumor Consortium Memphis, Tennessee, United States, 38105 St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Texas Children's Hospital Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Collapse << |
NCT00357305 | Accelerated Phase Chronic Myel... more >>ogenous Leukemia Adult Acute Basophilic Leukemia Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Blastic Phase Chronic Myelogenous Leukemia Chronic Eosinophilic Leukemia Chronic Myelomonocytic Leukemia Chronic Neutrophilic Leukemia de Novo Myelodysplastic Syndromes Essential Thrombocythemia Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Polycythemia Vera Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 Collapse << |
NCT01153672 | - | - | Completed | - | - |
NCT01501370 | Multiple Myeloma | Phase 2 | Withdrawn | - | Italy ... more >> Clinica di Ematologia, A.O.U. Ospedali Riuniti, Ospedale Umberto I di Ancona Ancona, Italy, 60020 U.O.S. di Ematologia, Ospedale Mazzoni Ascoli Piceno, Italy, 63100 Dh ematologia, A.O.U. Careggi Firenze, Italy, 50139 Ematologia, Ospedale S. Maria della Misericordia Perugia, Italy, 06156 Ematologia e Immunoematologia, Azienda Ospedaliera Riuniti Marche Nord Pesaro, Italy, 61100 Dip. Ematologia-U.O di Ematologia Generale-Azienda USL di Pescara-P.O. dello Spirito Santo Pescara, Italy, 65100 Ematologia , A.O.U. Pisana Pisa, Italy, 56126 Universitaria di Ematologia, A.O.U. San Giovanni Battista di Torino, Torino, Italy, 10126 Collapse << |
NCT01153672 | Male Breast Cancer ... more >> Recurrent Breast Cancer Stage IV Breast Cancer Collapse << | Not Applicable | Completed | - | United States, Washington ... more >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Collapse << |
靶点 | Description | IC50 |
---|---|---|
HDAC1 | IC50:~10nM | |
HDAC3 | IC50:~10nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网